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I  Introduction 
I.1  Leukocyte adhesion and transendothelial migration 
Leukocyte emigration from the bloodstream and to a site of tissue inflammation involves the 
sequential action of traffic signals and adhesion molecules mediating rolling, arrest, and 
diapedesis (Springer, 1994). At sites of inflammation, the vessel wall displays specific 
combinations of traffic signals that can recruit specific subsets of leukocytes to traverse it. 
The initial attachment to the vessel wall is mediated by selectins. The rapid ligand interaction 
and dissociation rate of selectins allow leukocytes to tether and roll along endothelial cells 
under shear flow (Fig. I-1). Rolling slows down flowing leukocytes, bringing them into close 
proximity with endothelial cells, and facilitating encounters of specific G-protein coupled 
chemokine receptors expressed on leukocytes with the corresponding chemokines displayed 
on the apical surface of inflamed endothelium. Activation of chemokine receptors triggers 
intracellular signaling pathways that activate leukocyte integrins. Interactions between 
integrins and their ligands expressed on the endothelium mediate firm adhesion of leukocytes 
to the endothelium. Firm adhesion to the endothelium is followed by transendothelial 
migration of leukocytes from the vascular lumen into the extravascular space and chemotaxis 
towards site of inflammation (Alon and Feigelson, 2002; Weber, 2003).  
Figure I-1. Leukocyte extravasation from the blood flow and into inflamed tissue follows a multistep cascade 
involving the sequential action of selectins, chemokines, and integrins and their ligands from the 
Immunoglobulin superfamily (IgSF). The steps involved in this process are tethering, rolling, integrin activation, 
firm adhesion, transmigration, and chemotaxis. Adapted from Sackstein, 2005.  
Tethering Rolling Activation Firm 
adhesion
Transmigration Chemotaxis
Selectins
Integrins and IgSF members
Chemokines
Endothelium
Blood
Tissue
Leukocyte
Chemokines 
at site of 
inflammation
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1.2  Chemokines 
Chemokines are a family of small (6-14 kDa) chemotactic secreted proteins that function in 
leukocyte trafficking by stimulating the directional migration of leukocytes. Chemokines are 
also involved in other biological processes including growth regulation, haematopoiesis, 
embryologic development, and angiogenesis. Approximately 40 different chemokines have 
been identified so far, which interact with about 17 different chemokine receptors expressed 
on different subsets of leukocytes. Chemokines are classified in four subgroups according to 
the position of the N-terminal cysteines. The majority of chemokines belong to the CC or 
CXC group, where the two N-terminal cysteines are immediately adjacent to each other (CC) 
or separated by one amino acid (CXC). Fractalkine is the only member of the CX3C group 
where the N-terminal cysteines are separated by three amino acids. Fractalkine is also the only 
chemokine that exist in both a membrane-anchored form with a mycin-like stalk and a shed 
soluble form (Bazan et al., 1997). Chemokines belonging to the C group of chemokines 
possesses only two of the four cysteines present in other chemokines (Moser and Willimann, 
2004; Weber et al., 2004).  
 
Chemokines exert their biological effects by interacting with specific chemokine receptors 
expressed on leukocytes. Chemokine receptors are seven transmembrane-spanning receptors 
that signal through coupled heterotrimeric G proteins. Chemokine receptor binding induces a 
signal transduction cascade that leads to activation of protein kinases and an increase in 
intracellular Ca2+ (Horuk, 2001).  
 
Recruitment of circulating leukocytes is largely regulated by chemokines and their receptors. 
Chemokines binds to extracellular proteins like glycosaminoglycans (GAGs) on the cell 
surface of endothelial cells thereby generating a solid phase chemokine gradient (Middleton et 
al., 2002). Triggering of chemokine receptors activates leukocyte integrins.  After leukocyte 
transmigration, liquid phase chemokine gradients induce leukocyte chemotaxis to site of 
inflammation. Each of the chemokines recognizes and induces the chemotaxis of a particular 
subset of leukocytes.  
 
I.3  Integrins 
Integrins are a large family of cell surface receptors expressed by nearly all cell types and 
involved in intercellular interactions and in cell interactions with extracellular matrix 
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glycoproteins. Integrins play an important role in various processes such as inflammation, 
cytoskeletal organization, hemostasis, wound healing, cell proliferation and differentiation. 
Integrins are heterodimers consisting of two type I transmembrane glycoprotein, one α-
subunit and one β-subunit, which are non-covalently linked. 18 different α-subunits and 8 
different β-subunits have been identified, forming at least 24 different heterodimers with 
distinct but sometimes overlapping expression pattern, binding specificity and signaling 
properties (Shimaoka et al., 2002; Springer and Wang, 2004). Integrins play an important role 
in leukocyte recruitment, where the most important integrins are very late antigen-4 (VLA-4, 
α4β1, CD49d/CD29), lymphocyte function-associated antigen-1 (LFA-1, αLβ2; 
CD11a/CD18), macrophage antigen-1 (Mac-1, αMβ2, CD11b/CD18), and p150,95 (αXβ2, 
CD11c/CD18).  
 
I.3.1  Integrin structure 
The shape of the integrin is a globular ligand-binding headpiece, which is connected by two 
long stalk regions to the transmembrane and C-terminal cytoplasmic domains (Springer and 
Wang, 2004). The α-subunits vary between 120-180 kDa. The N-terminus of the α subunit 
contains seven homologous segments of about 60 amino acids each (Fig. I-2A), which are 
predicted to fold into a seven-bladed β-propeller domain (Springer, 1997). Half of integrin α-
subunits contain an inserted domain called the I domain. The I domain consist of about 200 
amino acids and is inserted between β-sheet 2 and 3 in the β-propeller domain. A divalent 
cation coordination site for Mg2+ and Mn2+ designated the metal ion-dependent adhesion site 
(MIDAS) is located in the I domain (Lee et al., 1995). The I domain is frequently the major 
ligand-binding domain when present, whereas the β-propeller domain seems to directly 
participate in ligand binding in integrins without an I domain. In I domain containing 
integrins, the β-propeller domain sometimes participate in ligand binding. The region C-
terminal to the β-propeller domain in the extracellular part of the α-subunit has been predicted 
to fold into three β-sandwich domains designated the Thigh, Calf-1, and Calf-2 domains. The 
extracellular domain is followed by the transmembrane domain, which traverses the 
membrane only once. The cytoplasmic domain of α-subunits vary between 20-50 amino acids 
with high heterogeneity resulting in a high variability of signal properties of integrins 
(Shimaoka et al., 2002).  
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Figure I-2. Schematic representation of the domain structure of the integrin LFA-1 (αLβ2). (A) Organization of 
domains within the primary structure of the αL and β2 subunits of LFA-1. The I domain in the αL subunit is 
inserted between β sheets W2 and W3 in the β-propeller domain. The β-propeller domain (W1-W7) is followed 
by the three β-sandwich domains Thigh, Calf-1, and Calf-2, a transmembrane domain, and a short cytoplasmic 
domain. The β2 subunit contains a PSI (plexin-semaphorin-integrin) domain followed by the I-like domain 
inserted in the hybrid (H) domain, four I-EGF (integrin-epidermal growth factor) domains (E1-E4), a β-tail (β-
TD) domain, a transmembrane domain, and a short cytoplasmic domain. Dark dots denote Mg2+ binding sites in 
the I domain and the I-like domain, and light dots denote Ca2+ binding sites. (B, C) Arrangement of domains 
within the three-dimensional structure with the αL subunit shown in white and the β2 subunit shown in black. (B) 
low-affinity bent conformation (C) high-affinity extended conformation. Adapted from Shimaoka et al., 2002.  
 
 
The size of the β-subunit vary between 95-117 kDa. The N-terminal region contains a 
cysteine-rich region termed the PSI (plexin-semaphorin-integrin) domain. The first cysteine in 
the PSI domain forms a long-range disulfide-bridge to the C-terminal portion of the 
extracellular domain of the β-subunit. The β-subunit contains a domain with a putative metal-
cytoplasmic
region
A
W1 W2 I domain W3 W4 W5 W6 W7 Thigh Calf-1 Calf-2
I-like domain E4E3E2E1
αL
β2
COOH
COOH
H2N
H2N
Hybrid domain
I domain
I-like
H
E3
E4
β-TD
β-propeller
Thigh
Calf-1
Calf-2
E1+E2
PSI
extracellular region plasma
membraneβ-propeller domain repeats
I-EGF domains
β-TDPSI
B
C
αL αLβ2 β2
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binding motif similar to that of the MIDAS in the I domain of the α-subunit and with weak 
sequence homology to the I domain (Goodman and Bajt, 1996), which has been termed the I-
like domain. The I-like domain is inserted in the hybrid domain. The C-terminal of the 
extracellular part of the β-subunit contains the domains in the stalk region. These are the β-
tail domain (β-TD) and the four I-EGF (integrin-epidermal growth factor) domains, which are 
important in signal transmission. The transmembrane domain traverses the membrane only 
once as for α-subunits. The cytoplasmic domain of β-subunits vary between 15-65 amino 
acids, with the cytoplasmic domain of the β4-subunit of about 1000 amino acids as the only 
exception. The cytoplasmic domains of the β-subunits share high homology in contrast to the 
cytoplamic domains of α-subunits (Springer and Wang, 2004).  
 
I.3.2  Integrin activation and signaling 
Since integrins are important in biological processes requiring rapid modulation of adhesion 
and detachment, and since integrin ligands are widely expressed, interactions between 
integrins and their ligands must be tightly controlled. Integrins are not fixed in a particular 
conformation, but equilibrate between a low-affinity bent conformation and a high-affinity 
extended conformation (Fig. I-2B and C). The headpiece of the integrin faces down towards 
the membrane in the bent inactive conformation and extends upward upon activation (Takagi 
et al., 2002; Takagi and Springer, 2002). Whether the equilibrium favors the bent or the 
extended conformation is affected by the presence of activating factors. Activation by signals 
within the cell (inside-out signaling) such as intracellular signals caused by chemokine 
receptor activation or phorbol esters such as phorbol-12-myristate-13-acetate (PMA) induces 
and stabilizes the extended conformation. Binding of the divalent cations  Mg2+ or Mn2+ to the 
extracellular part of the integrin (outside-in signaling) also favors the extended conformation 
(Dransfield et al., 1992). Transition from the bent to the extended conformation is associated 
with a separation of the transmembrane and cytoplasmic domains of the α- and the β-subunit 
(Kim et al., 2003), allowing a bi-directional exchange of signals between the integrin 
headpiece and the cytoplasmic domains. The rapid modulation of integrin affinity allows 
integrin activation in less than one second (Diamond and Springer, 1994).  
 
Integrins have several binding motifs for divalent cations (Fig I-2A), which have multiple 
effects on integrin-ligand interactions including suppression, enhancement, and modifications 
of ligand binding affinity. For many integrins, Mg2+ and Mn2+ can induce conformational 
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changes that result in higher affinity to ligand, whereas Ca2+ often has an inhibitory effect on 
ligand binding. This is for example the case for the integrin LFA-1, where stimulation with 
Mg2+ requires chelation of Ca2+ with EGTA in order to induce higher affinity to ICAM-1 
(Dransfield et al., 1992; Stewart et al., 1996). 
 
The adhesiveness of integrins is not only regulated by affinity to ligand, but also by avidity 
regulation through clustering of integrins on the cell surface. This has been shown for LFA-1, 
where chemokines stimulate LFA-1 lateral mobility leading to LFA-1 clustering into large 
polar patches (Constantin et al., 2000). A dynamic regulation of LFA-1 avidity is also 
important in transendothelial chemotaxis (Weber et al., 1997a).  
 
I.3.3  I domain 
The I domain is frequently the major ligand-binding domain in I domain containing integrins. 
I domain-deleted LFA-1 is unable to bind its ligands ICAM-1 and ICAM-3 (Leitinger and 
Hogg, 2000; Yalamanchili et al., 2000). In contrast, I domain-deleted Mac-1 can bind at 
reduced levels to some Mac-1 ligands, including factor X and iC3b, but not fibrinogen. The β-
propeller domain of the αM subunit of Mac-1 seems to be important for these interactions, 
since binding could be inhibited with a mAb specific for the β-propeller domain of αM 
(Yalamanchili et al., 2000).  
 
The ability of the I domain to bind ligand is controlled by conformational changes in the I 
domain. Two different conformations of the I domain have been described; a low affinity 
closed conformation and a high affinity open conformation, which differ in the side chains 
that coordinate the Mg2+ ion in the MIDAS. Disulfide bonds have been mutationally 
introduced in the αL I domain of LFA-1 to stabilize the conformation with either low or high 
affinity for ligand. In the transitions to the open conformation there is a downward movement 
of the C-terminal α6-helix, which is linked to alterations of the MIDAS loops and Mg2+ 
coordination (Fig. I-3). Locking the αL I domain in the open high-affinity conformation by the 
introduction of a disulfide bond resulted in 9000-fold increased affinity of LFA-1 to the 
ligand ICAM-1. This increase in affinity could be reversed by disulfide reduction (Shimaoka 
et al., 2001).   
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Figure I-3. Stereodiagram of mutant αL I domains with mutations to introduce a disulfide bond.  (A) The double 
mutation L289C/K294C introduces a disulfide bond, that locks the αL I domain in the closed low-affinity 
conformation. (B) The double mutation K287C/K294C introduces a disulfide bond, that locks the αL I domain in 
the open high-affinity conformation. For clarity, only residues 254-305 of the αL I domain are shown. The 
downward movement of the α6 helix in the open conformation is readily apparent (Shimaoka et al., 2001).  
 
 
I.3.4  Integrin ligands 
Some integrins bind ligands in the extracellular matrix (ECM). These ligands include 
collagen, fibronectin, vitronectin, laminin, thrombospondin, and osteopontin. Collagens are a 
family of fibrous proteins and as a major component of skin and bone they are the most 
abundant proteins in mammals. Collagens serves as counter-receptors for some β1 and β3 
integrins. Fibrinogen, which is a dimeric soluble plasma protein important in blood clotting, 
wound healing and inflammation, is a ligand for integrins including Mac-1, αXβ2, αIIbβ3, and 
αVβ3 (Berman et al., 2003; Springer and Wang, 2004).  
 
The integrin counter-receptors on the cell surface include members of the immunoglobulin 
superfamily (IgSF), which is a large group of transmembrane glycoproteins composed of 2-9 
IgSF domains in tandem on the cell surface. The immunoglobulin domains share homology 
with the variable (type V) and constant (type C1 and C2) domains of antibodies (Bork et al., 
1994). The Ig-like domains are built from a tightly packed barrel of either 7 (in C1 and C2 
domains) or 9 (in V domains) β-strands arranged in two layers. In spite of the very conserved 
patterns of domain folding and organization in members of the IgSF, there is a great diversity 
in their modes of interaction. Binding sites can be localized to a single domain or involve 
several domains. The sites can be located in membrane distal domains, internal domains, or in 
membrane proximal domains. Furthermore, binding may be influenced by glycosylation of 
BA
N
C
N
C
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the Ig-like domains (Holness and Simmons, 1994). The IgSF is the most abundant family of 
cell surface molecules, accounting for about 50% of leukocyte surface glycoproteins. 
Members of the family include T-cell receptor (TCR), CD8, CD4, growth factor receptors 
such as CSF-1 receptor and PDGF receptor, and cell adhesion molecules (Holness and 
Simmons, 1994). 
 
The interactions between integrins and cell adhesion molecules are important in leukocyte 
adhesion and diapedesis. The intercellular adhesion molecules (ICAMs) are ligands for the 
integrin LFA-1, vascular cell adhesion molecule-1 (VCAM-1) is a ligand for the integrin 
VLA-4, and mucosal addressin cell adhesion molecule-1 (MAdCAM-1) is a ligand for the 
integrin α4β7. Recently, also the junctional adhesion molecules (JAMs) have been identified 
as integrin ligands. JAM-A is a ligand for LFA-1 (Ostermann et al., 2002), JAM-B is a ligand 
for VLA-4 (Cunningham et al., 2002), and JAM-C is a ligand for Mac-1 (Santoso et al., 
2002).  
 
I.3.5 LFA-1 
Lymphocyte-function associated antigen-1 (LFA-1) is one of the most abundant integrins and 
is expressed exclusively on leukocytes (Kurzinger et al., 1981; Larson et al., 1989). LFA-1 is 
involved in a wide range of immunological processes, including leukocyte migration into sites 
of inflammation, lymphocyte homing, interactions of T cells with antigen-presenting cells, 
and B lymphocyte responses (Arnaout, 1990; Dustin et al., 1989; Springer et al., 1987) by 
interaction with its ligands ICAM-1 (Dustin et al., 1989), ICAM-2 (Staunton et al., 1989), 
ICAM-3 (de Fougerolles and Springer, 1992), and JAM-A (Ostermann et al., 2002). The 
importance of β2 integrins such as LFA-1 is evident from patients with leukocyte adhesion 
deficiency-1 (LAD-1), where the expression of the β2 integrins LFA-1, Mac-1, and p150,96 
on the surface of leukocytes is lacking. Patients with LAD-1 suffer from severe and recurrent 
infections as a result of an impairment of a wide range of leukocyte adhesion-dependent 
functions (Marlin et al., 1986).   
 
I.4  Junctional adhesion molecule-A 
The junctional adhesion molecules (JAMs) are transmembrane proteins belonging to the IgSF 
proteins. The first JAM protein to be identified was JAM-A (CD321; also called JAM, 
JAM-1, F11-Receptor; for new nomenclature of JAM proteins see Bazzoni, 2003) originally 
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referred to as the F11-receptor, because it was identified as the receptor for a platelet 
activating antibody F11 (Kornecki et al., 1990). The full-length sequence of murine JAM-A 
was first identified (Martin-Padura et al., 1998) followed by the identification of the human 
homologue (Ozaki et al., 1999; Williams et al., 1999). Since these first studies were done 
using endothelial and epithelial cells, the protein was named junctional adhesion molecule 
based on its cellular localization in these cells. JAM-A is highly conserved among mammals, 
with human, murine, bovine, and rat JAM-A displaying about 70% amino acid identity (Liu et 
al., 2000; Martin-Padura et al., 1998).  
 
I.4.1 JAM-A expression and localization   
Human JAM-A is expressed in lymphocytes, monocytes, neutrophils and platelets (Williams 
et al., 1999), whereas murine JAM-A expression has been reported in platelets and MHC 
class II antigen-presenting cells of lymphoid organs (Malergue et al., 1998). In addition, 
JAM-A is expressed in endothelial and epithelial cells (Martin-Padura et al., 1998; Williams 
et al., 1999) in tissues that include liver, kidney, pancreas, heart, brain, lymph nodes, 
intestine, lung, placenta, and vascular tissue (Aurrand-Lions et al., 2001; Liang et al., 2000; 
Liu et al., 2000; Martin-Padura et al., 1998). In endothelial and epithelial cells JAM-A 
localizes to the apical region of intercellular junctions called the tight junctions (TJs). The 
junctional localization of JAM-A can be influenced by inflammatory cytokines. The 
combined treatment of endothelial monolayers with TNF-α and IFN-γ causes a redistribution 
of JAM-A from the intercellular junctions to the cell surface (Ozaki et al., 1999). This 
cytokine treatment does not change JAM-A gene expression at the mRNA level (Gupta et al., 
2000) or the amount of JAM-A on the cell surface found by flow cytometry analysis (Ozaki et 
al., 1999).  
 
I.4.2 Structure of JAM-A 
The extracellular part of JAM-A contains two Ig-like domains each flanked by two cysteine 
residues forming a disulfide bond. The extracellular domain is followed by a single-span 
transmembrane segment and a short cytoplasmic tail. The crystal structures of the 
extracellular domain of murine JAM-A (Kostrewa et al., 2001) and  human JAM-A (Prota et 
al., 2003) have been resolved. The crystal structures revealed that a short linker of 3 amino 
acids (VLV) connects the two Ig-like domains in a bent conformation with an elbow angle of 
about 125°, which is stabilized by extensive hydrogen bonding to both domains (Kostrewa et 
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al., 2001). The membrane-distal domain 1 (D1) of JAM-A contains a dimerization motif 
(RVE) involved in homodimer formation (Fig. I-4). The membrane-proximal domain 2 (D2) 
of human JAM-A contains two N-glycosylation sites (N185 and N191), which leads to 
heterogeneous expression in some cells due to different glycosylation. The cytoplasmic tail of 
JAM-A is highly charged and contains a putative phosphorylations site for PKC as well as the 
PDZ-binding motif FLV at the C-terminus.  
 
 
Figure I-4. Structure of human JAM-A. Ribbon drawings of the human JAM-A dimer with one monomer shown 
in blue and the other in orange. Two orthogonal views are displayed (A and B). Disulfide bonds are shown in 
green. The interface is formed by residues of the two D1 domains (Prota et al., 2003).  
 
I.4.3 Extracellular homophilic interactions in cis and in trans 
Through the dimerization motif RVE in the domain D1, JAM-A forms in cis non-covalent 
homodimers (Fig. I-4). Together with the bent conformation imposed by the VLV linker, the 
dimerization results in homodimers, that emerge from the cell surface with the shape of an 
inverted U. These in cis homodimers predictably bind homophilic in trans with JAM-A 
homodimers that emerge from an neighboring cell (Kostrewa et al., 2001). The JAM-A 
homophilic interactions in trans between neighboring cells stabilize intercellular junctions 
and reduce paracellular permeability of confluent cell monolayers (Martin-Padura et al., 
1998). JAM-A homophilic interactions in trans could be blocked using a monoclonal 
antibody specific for the dimeric state of JAM-A (Bazzoni et al., 2000a). The JAM-A 
homophilic interactions were shown to be important for localization of JAM-A at TJs and for 
regulation of barrier function in epithelial cells (Mandell et al., 2004).  
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I.4.4 Extracellular heterophilic interactions 
JAM-A has been identified as a ligand for the leukocyte integrin LFA-1 (Ostermann et al., 
2002). The interaction is mediated by the domain D2 of JAM-A as shown by expression of 
JAM-A domain deletion mutants. In addition, JAM-A is a reovirus receptor (Barton et al., 
2001). Reovirus attachment to cells is mediated by the binding of the viral attachment protein 
σ1 to JAM-A. The domain D1 of JAM-A is necessary and sufficient for interaction with σ1 
(Prota et al., 2003).  
 
I.4.5 Intracellular heterophilic interactions 
The cytoplasmic tail of JAM-A contains the amino acid residues FLV at its C-terminus, 
which represents a binding motif for type II PDZ domains (named after the first family 
members PSD-95, DLG, and ZO-1). PDZ domains are protein interaction domains that bind 
in a sequence specific manner to short C-terminal or internal sequences. They have similar 
architectures consisting of six antiparallel β-strands arranged in a β-sandwich flanked by two 
α-helices (Sheng and Sala, 2001). Since PDZ proteins often have multiple PDZ domains 
sometimes with distinct binding specificities, they are considered to function as scaffolding 
proteins that promote the clustering of protein complexes at specific subcellular sites (Pawson 
and Scott, 1997).  
 
JAM-A has been reported to associate with at least five different proteins containing PDZ 
domains. The junctional protein ZO-1 (zonula occludens-1) binds directly to JAM-A with its 
PDZ domain 2 and 3 (Ebnet et al., 2000). JAM-A also interacts with the PDZ domain of the 
junctional protein AF-6 (ALL-1 fusion partner from chromosome 6) (Ebnet et al., 2000). 
AF-6 and ZO-1 are both directly linked to the actin cytoskeleton (Fanning et al., 1998; 
Mandai et al., 1997), which allows JAM-A to be anchored to the actin filament system via its 
binding to AF-6 and ZO-1. AF-6 also interacts with ZO-1 and with the small GTPase Ras. A 
third intracellular interaction partner for JAM-A is CASK (calcium/calmodulin-dependent 
serine protein kinase), which also associate with JAM-A in a PDZ-domain dependent manner 
(Martinez-Estrada et al., 2001). The interaction with CASK is not required for recruitment of 
JAM-A to TJs, since JAM-A is recruited to TJs early during junction formation, while CASK 
appears at junctions at a later time point. The junctional protein ASIP (atypical PKC isotype-
specific interacting protein) is the vertebrate orthologue of PAR-3. ASIP associate in a 
signaling complex with PAR-6, the small GTPase Rac1/cdc42 and atypical protein kinase C 
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(aPKC). In addition, JAM-A interact with the first PDZ domain of ASIP, which might be 
involved in recruitment of this signaling complex to TJs (Ebnet et al., 2001; Itoh et al., 2001). 
MUPP1 (multi-PDZ domain protein 1) is a junctional protein with 13 PDZ domain, which 
might function as a multivalent scaffold protein that recruits various proteins to TJs. MUPP1 
binds claudin-1 with its PDZ domain 10 and JAM-A with its PDZ domain 9 (Hamazaki et al., 
2002). Finally, JAM-A colocalizes with the TJ proteins cingulin and occludin, possible 
through the interactions with ZO-1 (Bazzoni et al., 2000b).  
I.4.6 Functions of JAM-A 
JAM-A has been implicated in a variety of processes. Through the many intracellular 
interactions with other tight junction proteins and with proteins linked to the cytoskeleton, 
JAM-A may play a central role in TJ assembly and maintenance. The integrity of intracellular 
junctions is important for barrier function and the regulation of paracellular permeability (Liu 
et al., 2000).  
 
Being localized at the apical part of intracellular spaces, JAM-A may also play an important 
role in inflammation in particular leukocyte transmigration. Leukocyte adhesion may also be 
influenced by JAM-A expressed on leukocytes and on the surface of endothelial cells after 
chemokine-induced redistribution. Several reports have shown a role of JAM-A in 
transmigration. Monocyte transmigration was inhibited by a mAb against JAM-A (Martin-
Padura et al., 1998). In mice, a mAb against JAM-A significantly inhibited leukocyte 
accumulation in the cerebrospinal fluid and infiltration in the brain parenchyma (Del Maschio 
et al., 1999). Both JAM-A homophilic interactions and heterophilic interactions with the 
integrin LFA-1 may be involved. Furthermore, dendritic cell (DC) motility and transmigration 
across lymphatic endothelial cells was increased in JAM-A- deficient mice (Cera et al., 2004). 
Neutrophils from JAM-A-deficient mice showed reduced diapedesis in peritonitis and heart 
ischemia-reperfusion injury (Corada et al., 2005). Another report using JAM-A-deficient 
mice showed enhanced random motility of JAM-A-deficient endothelial cells, showing a role 
of JAM-A in cell motility through the interactions with the junctional complex and the 
cytoskeleton (Bazzoni et al., 2005). Using small interfering RNA (siRNA) downregulation of 
JAM-A expression, it was shown that decreased JAM-A expression results in decreased β1 
expression and Rap1 activity (Mandell et al., 2005).  
 
JAM-A expressed in platelets plays a role in platelet activation (Sobocka et al., 2000), and 
induces platelet adhesion to cytokine-stimulated endothelial cells, which suggest a role of 
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JAM-A in atherosclerosis and thrombosis (Babinska et al., 2002). JAM-A has also been 
reported to play a role in fibroblast growth factor-2 (FGF-2) induced angionesis (Cooke et al., 
2006; Naik et al., 2003a), and FGF-2 induced migration on vitronectin (Naik et al., 2003b). 
Finally, JAM-A is a receptor for reovirus (Barton et al., 2001; Campbell et al., 2005). An 
antibody against JAM-A could block reovirus adhesion and infection (Barton et al., 2001).  
 
I.4.7 Other JAM family members 
Subsequently, additional members of the JAM family of adhesion molecules have been 
identified. While displaying differential tissue and cellular expression, all JAMs localize to 
sites of endothelial or epithelial cell-cell contacts. JAM-B (formerly named VE-JAM, human 
JAM-2, murine JAM-3) has a more restricted distribution than JAM-A. It localizes to 
junctions of endothelial cells; in particular in high endothelial venules (HEVs) (Palmeri et al., 
2000) and in the heart (Cunningham et al., 2000). Expression of JAM-B was not detected in 
leukocytes (Cunningham et al., 2000). JAM-B has been reported to interact with the 
leukocyte integrin VLA-4 and with JAM-C (Arrate et al., 2001; Cunningham et al., 2002).  
 
JAM-C (formerly named human JAM-3, murine JAM-2) is expressed in endothelial cells, 
platelets, and lymphocytes (Arrate et al., 2001; Liang et al., 2002). JAM-C is a ligand for the 
integrin Mac-1 (Santoso et al., 2002), and has been reported to be involved in neutrophil 
transmigration (Aurrand-Lions et al., 2005; Zen et al., 2004).  
 
JAM-4 is expressed at TJs in epithelial cells and interacts with the PDZ domain of MAGI-1 
(Hirabayashi et al., 2003). JAM-L is prominently expressed in leukocytes and facilitate cell 
adhesion to endothelial cells (Moog-Lutz et al., 2003) and neutrophil migration by interaction 
with CAR (coxsackie and adenovirus receptor) expressed on epithelial cells (Zen et al., 2005).  
 
I.5  Inflammation in atherosclerosis 
Cardiovascular disease is currently among the most prevalent causes of death and illness in 
developed countries. Atherosclerosis, which is characterized by the accumulation of lipids 
and lesion formation in the arteries, is one of the most important contributors to 
cardiovascular disease (Hansson, 2001; Libby, 2002). Over the past years, it has become 
evident that inflammation plays a prominent role in atherosclerosis. Atherosclerotic lesions 
contain a large number of immune cells, particularly monocytes and T lymphocytes (Hansson 
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et al., 1989; Jonasson et al., 1986; Stemme et al., 1992). These cells may be involved in the 
initiation, progression, and development of atherosclerosis.  
 
After inflammatory activation, the endothelial cells increase their expression of various cell 
adhesion molecules, leading to increased attachment and diapedesis of circulating leukocytes 
contributing to the development of atherosclerotic lesions. Chemotactic transmigration of 
leukocytes through the endothelial layer and into the intima is enhanced by the secretion of 
chemokines by endothelial cells, smooth muscle cells, T lymphocytes, and intimal 
macrophages during lesion formation (Weber et al., 2004). Activated T lymphocytes and 
monocytes in atherosclerotic lesions secrete cytokines such as IL-1, IL-6, and TNF-α which 
amplify the local inflammatory response (Kishikawa et al., 1993). The chemokine KC 
triggers monocyte arrest on early atherosclerotic endothelium (Huo et al., 2001) and other 
chemokines such as MCP-1 (Takeya et al., 1993) and RANTES (Pattison et al., 1996) have 
been found in atherosclerotic lesions. After transmigration of monocytes into the arterial 
intima, monocytes differentiate into tissue macrophages. The macrophages accumulate lipids 
and give rise to foam cells, which leads to the formation of fatty streak, the initial lesion of 
atherosclerosis. Foam cells secrete pro-inflammatory cytokines and contribute to intima 
expansion and narrowing of the vessel lumen (Gerrity, 1981). The cellular composition of 
human atherosclerotic plaques is mainly macrophages, smooth muscle cells, and T 
lymphocytes. About 60% of plaque T lymphocytes are memory T cells, many of which are in 
a state of late or chronic activation (Stemme et al., 1992).  
 
The inflammatory recruitment of mononuclear cells is a process of central importance in 
initiation and progression of human atherosclerotic plaques, and has become a new 
therapeutic target in the prevention and treatment of atherosclerosis  
 
I.6  Aim of this study  
Interactions between the β2 integrin LFA-1 (αLβ2) and JAM-A has been shown to enhance 
leukocyte adhesion and transendothelial migration. Since the location of the JAM-A binding 
domain in LFA-1 has not been identified, it was here analyzed whether the I domain of 
LFA-1 contains a ligand-binding domain for interactions with JAM-A. Furthermore, the 
involvement of JAM-A in distinct steps of mononuclear cell recruitment was analyzed using 
soluble forms of JAM-A as a competitive inhibitor. To explore the role of JAM-A in 
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atherosclerosis, the expression of JAM-A on early atherogenic endothelium was analyzed and 
the atherogenic recruitment of mononuclear cells was investigated. Finally, the role of 
endothelial JAM-A in monocyte adhesion and transmigration was investigated using 
endothelial cells isolated from JAM-A-deficient mice (Figure I-5).  
 
 
To summarize, in the present study the following questions were addressed:  
 
- does the I domain of LFA-1 contain a functional binding domain for JAM-A? 
 
- can the inflammatory recruitment of mononuclear cells be inhibited by soluble forms 
of JAM-A? 
 
- is JAM-A expressed on atherosclerotic endothelium? 
 
- does JAM-A participate in atherogenic recruitment of mononuclear cells? 
 
- what is the role of endothelial JAM-A in monocyte adhesion and transmigration? 
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Figure I-5. Flow chart diagram of experimental procedures used in this thesis. 
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II  Materials and Methods 
Protocols were adapted from standard protocols (Sambrook and Russell, 2001) if not stated 
otherwise. All solutions were prepared with double distillated water (Heraeus Destamat, 
Heraeus, Germany) or Millipore water (Milli-Q Plus ultrapure purification, Millipore, MA). 
Reagents were from Fluka (Buchs, Switzerland), Sigma (Deisenhofen, Germany), or Roth 
(Karlsruhe, Germany) if not stated otherwise. All animal studies were approved by local 
authorities and complied with German animal protection law.  
 
II.1 General equipment 
autoclave  Systec 2540EL (Systec, Wettenberg, Germany) 
balance  Analytical Plus, (Ohaus, Pine Brook, NJ, USA) 
centrifuges  Eppendorf  5417C (Eppendorf, Hamburg, Germany), 
Heraeus Labofuge 400 and Heraeus Multifuge 3 S-R (Heraeus, 
Osterode, Germany) 
electroporator  Gene-pulser II (Bio-Rad, Hercules, CA, USA) 
flow cytometer FACSCalibur (BD Biosciences, San Jose, CA, USA) 
fluorescence plate reader SpectraFluor Plus (Tecan, Crailsheim, Germany) 
gel electrophoresis  Mini-sub cell GT (Bio-Rad, Hercules, CA, USA) 
laminar flow hood Herasafe (Heraeus, Osterode, Germany) 
microscopes  Olympus IX71 and BX51 (Olympus Optical, Hamburg, 
Germany), Leica DMLB (Leica, Wetzlar, Germany) 
PCR thermocycler MyCycler (Bio-Rad, Hercules, CA, USA) 
DNA Engine Opticon (MJ Research, Hercules, CA, USA) 
pH-meter  InoLab level 1 (WTW, Weilheim, Germany) 
spectrophotometer GeneQuant (Amersham Biosciences, Uppsala, Sweden)  
   
II.2 General solutions 
 
HBSS Hanks’ balanced salt solution (Gibco BRL, Karlsruhe, 
Germany) 
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HHMC  HBSS, 0.5% (w/v) BSA, 10 mM HEPES, pH 7.4, 1 mM MgCl2, 
1 mM CaCl2 
MOPS-buffer  1% (w/v) human serum albumin, 145 mM NaCl, 4.7 mM KCl, 2 
mM CaCl2, 1.2 mM MgSO4, 5 mM glucose, 2 mM sodium 
pyruvate, 2 mM MOPS, and 1.2 mM NaH2PO4, pH 7.5  
PBS  137 mM NaCl, 2.7 mM KCl, 1.5 mM KH2PO4, 8 mM Na2HPO4, 
pH 7.4 (PAA laboratories, Linz, Austria)  
TBS 137 mM NaCl, 2.7 mM KCl, 25 mM Tris-HCl, pH 7.4 
 
II.3 Chemokines, antagonist, and recombinant proteins 
The chemokines TNF-α, IFN-γ, and SDF-1α were purchaced from PeproTech (Rochy Hill, 
NJ, USA) and PMA was from Calbiochem (Merck Biosciences, Darmstadt, Germany). The 
LFA-1 antagonist BIRT377 was kindly provided by Dr. T. Kelly (Boehringer Ingelheim 
Pharmaceuticals, Ridgefield, CT, USA). Recombinant JAM-A.Fc and ICAM-1.Fc chimeric 
protein was generated as described (see II.13.1). CD30.Fc protein was from R&D Systems 
(Minneapolis, MN, USA). Locked-open human LFA-1 I domain was kindly provided by 
Revotar Biopharmaceuticals (Henningsdorf, Germany).  
 
II.4 Antibodies 
II.4.1 Primary antibodies 
LFA-1: 
G25.2 mAb specific for the αL subunit of human LFA-1,  non-I domain 
specific, mouse IgG2a (BD Biosciences, San Jose, CA, USA)  
TS1/18 mAb specific for the β2 subunit of human LFA-1, mouse IgG1, 
purified from hybridoma cell supernatants by protein A 
chromatography 
TS1/22 mAb specific for the αL subunit of human LFA-1, I domain 
specific, mouse IgG1, purified from hybridoma cell supernatants 
by protein A chromatography 
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JAM-A: 
H202-106-7-4 mAb specific for murine JAM-A, rat IgG1, kindly provided by 
Dr. B. Imhof (University Medical Center, Geneva, Switzerland)  
JAM-A (246) pAb specific for human JAM-A, rabbit IgG, generated by 
protein immunization of rabbit, from rabbit 246 
JAM-A clone 43 mAb specific for human JAM-A, mouse IgG1 (BD Biosciences) 
JAM-A (R&D) pAb specific for murine JAM-A, goat IgG, (R&D Systems, 
Minneapolis, MN, USA) 
JAM-A (TS) pAb specific for human JAM-A, mouse IgG, generated by DNA 
immunization of mice, from mouse TS 
M.Ab.F11 mAb specific for human JAM-A, mouse IgG1 (Serotec, Oxford, 
UK) 
 
Others: 
HP2/1 mAb specific for the α4 subunit of human VLA-4, mouse IgG1 
(Immunotech, Marseille, France)  
ICAM-1 mAb specific for murine ICAM-1 (clone 3E2), hamster IgG1 
(BD Biosciences)  
ICAM-1 (G-5) mAb specific for human ICAM-1 (clone G-5), mouse IgG1 
(Santa Cruz) 
PECAM-1 (M-20) pAb specific for murine PECAM-1, goat IgG (Santa Cruz, Santa 
Cruz, CA, USA)  
VCAM-1 mAb specific for murine VCAM-1 (clone 429, MVCAM.A), 
Rat IgG2a (BD Biosciences) 
vWF pAb specific for von Willebrand Factor, rabbit IgG (Sigma, 
Deisenhofen, Germany) 
II.4.2 Secondary antibodies 
FITC anti-goat IgG FITC-conjugated anti-goat IgG, from rabbit (Sigma) 
FITC anti-hamster IgG FITC-conjugated anti-hamster IgG, from mouse (BD 
Biosciences) 
FITC anti-mouse IgG FITC-conjugated anti-mouse IgG, from goat (Sigma) 
FITC anti-rabbit IgG FITC-conjugated anti-rabbit IgG, from goat (Sigma) 
FITC anti-rat IgG FITC-conjugated anti-rat IgG, from rabbit (Sigma) 
HRP anti-human IgG HRP-conjugated anti-human IgG, Fc-specific (Sigma) 
II  Materials and Methods 20
HRP anti-rabbit IgG HRP-conjugated anti-rabbit IgG, from goat (Santa Cruz) 
HRP anti-mouse IgG HRP-conjugated anti-mouse IgG, from goat (Santa Cruz) 
II.4.3 Isotype controls 
goat IgG IgG from goat serum (Sigma) 
hamster IgG1 purified hamster IgG1 (BD Biosciences) 
human IgG (hIgG) IgG from human serum (Sigma) 
mouse IgG1  purified mouse IgG1 (Serotec) 
mouse IgG2a purified mouse IgG2a (Serotec) 
rabbit IgG IgG from rabbit serum (Sigma) 
rat IgG1 purified rat IgG1 (Serotec) 
rat IgG2a purified rat IgG2a (Serotec) 
 
II.4.4 Antibody purification from hybridoma cell supernatants  
B cell hybridomas are derived by cell fusion between a B lymphocyte from an immunized 
animal and a myeloma cell. The hybridoma cell lines TS1/18 and TS1/22 (Sanchez-Madrid et 
al., 1982) were from ATCC and cultured in DMEM medium supplemented with 10% (v/v) 
FCS ultra low IgG (Gibco BRL, Karlsruhe, Germany) and 50 µg/ml gentamicin.  
 
Protein G affinity chromatography was used for isolation of mouse IgG1 mAb secreted into 
the culture medium of hybridoma cells. A HiTrap Protein G Sepharose column, 1 ml volume 
(Amersham Biosciences, Uppsala, Sweden) was equilibrated with 10 volumes of 20 mM 
sodium phosphate, pH 7.0. The hybridoma cell supernatant was applied to the column and the 
column was washed with 10 volumes of 20 mM sodium phosphate, pH 7.0. Bound antibody 
was eluted with 0.1 M glycine, pH 3.0. and neutralized with 1 M Tris-HCl, pH 9.0 to final pH 
7.0. The protein concentration of elution fractions was measured by OD 280 and DC Protein 
Assay (Bio-Rad, Hercules, CA). All solutions used were filter sterilized.  
 
II.5 Mammalian cell culture procedures 
II.5.1 General 
Cell culture work with mammalian cells was done under sterile conditions in a laminar 
flowhood. Cells were maintained in a CO2-incubator at 37°C and a humidified 5% CO2 
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atmosphere. Cells were cultured in growth medium supplemented with 10-20% (v/v) fetal calf 
serum (FCS) and 50 µg/ml gentamicin to avoid contamination with bacteria. FCS was 
incubated at 56°C for 30 min to inactivate the complement system and stored at -20°C until 
use. All media and solutions for cell culture were from Gibco if not stated otherwise and 
purchased sterile or sterilized through a 0.2 µm filter. All cell lines were regularly tested to be 
mycoplasma free by the VenorGeM Mycoplasma detection kit (Minerva Biolabs, Berlin, 
Germany).  
 
II.5.2 Culturing of adherent cell monolayers 
Adherent cell lines were grown until confluence and then passaged by trypsinization. The 
monolayer was first washed with phosphate buffered saline (PBS) and then incubated 1-2 min 
with 0.25% (v/v) trypsin/0.04% EDTA at 37°C. After detachment of the monolayer, trypsin 
was inactivated by the addition of medium containing FCS. For subculturing, cells were 
harvested by centrifugation (5 min/200 g/RT) and then splitted with a subculturing ratio 
between 1:3 and 1:10.  
 
II.5.3 Culturing of cells in suspension 
Cells growing in suspension were cultured at a density of 105 - 106 cells/ml. Cells were 
harvested by centrifugation (5 min/200 g/RT).  
 
II.5.4 Freezing and thawing of mammalian cells 
Freeze stocks of cell lines were stored in 1.8 ml cryovials in liquid nitrogen. Cells were first 
harvested and then resuspended at a concentration of 106 - 107 cells/ml in ice-cold complete 
medium containing 10% (v/v) dimethylsulfoxide (DMSO). The cryovials were placed 
overnight at -80°C in a cryocontainer to assure slow cooling and then transferred to liquid 
nitrogen for long-term storage. For thawing of cells, cryovials were rapidly thawed in a 37°C 
water bath. Cells were slowly added to 4 ml warm growth medium, centrifuged and 
resuspended in growth medium in a culture flasks.  
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II.6 Mammalian cell lines 
II.6.1 Jurkat cells, clone E6-1 
The human T lymphocyte cell line Jurkat has been established from the peripheral blood of a 
patient with acute T cell leukemia. Cells were obtained from ATCC and propagated in RPMI 
1640 medium supplemented with 10% (v/v) FCS and 50 µg/ml gentamicin.  
 
II.6.2 J-β2.7 cells 
The J-β2.7 cell line is derived from Jurkat by chemical mutagenesis (Weber et al., 1997b). 
The J-β2.7 cells lack LFA-1 surface expression due to a deficiency of the αL subunit. The J-
β2.7 cells were propagated in the same growth medium as Jurkat cells. For propagation of J-
β2.7 transfectants, medium was supplemented with 800 µg/ml G418 sulfate.  
 
II.6.3 Mono Mac 6 cells 
The human monocytic cell line Mono Mac 6 (MM6) has been established from the peripheral 
blood of a patient with acute monocytic leukemia and was obtained from ATCC. MM6 cells 
were propagated in RPMI 1640 medium supplemented with 10% (v/v) FCS, 0.1 U/l 
penicillin, 100 µg/ml streptomycin, 1x MEM non-essential amino acid solution, 9 µg/ml 
insulin, 1 mM oxalacetate and 1 mM pyruvate. Cells were maintained in 24-well plates at a 
density between 2⋅105 – 106 cells/ml.  
 
II.6.4 Chinese hamster ovary cells 
The Chinese hamster ovary (CHO) cell line is an epithelial cell line initiated from an ovary 
biopsy of an adult hamster. The clone CHO-K1, which is a subclone from the parental CHO 
cell line, was obtained from The German Collection of Microorganisms and Cell Cultures 
(DSMZ). CHO cells were maintained in DMEM/F12-GlutaMax medium supplemented with 
10% (v/v) FCS and 50 µg/ml gentamicin. For propagation of CHO transfectants, growth 
medium was supplemented with 1000 µg/ml G418 sulfate. CHO cell lines with stable 
expression and secretion of JAM-A.Fc or ICAM-1.Fc soluble protein were available in the 
lab.  
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II.6.5 SVEC 
The SVEC cell line is an endothelial cell line derived by SV40 transformation of murine 
small vessel endothelial cells, originally isolated from the axillary lymph node vessels of an 
adult male C3H/Hej mouse. They were obtained from ATCC and cultured in DMEM 
supplemented with 10% (v/v) FCS and 50 µg/ml gentamicin.  
 
 
II.7 Primary cells 
II.7.1 Isolation of PBMCs 
Peripheral blood mononuclear cells (PBMCs) were isolated from venous blood of healthy 
volunteers by Ficoll-hypague density gradient centrifugation. After dextran sedimentation, the 
plasma supernatant was carefully overlayed on Biocoll separating solution, density 1.077 g/ml 
(Biochrom, Berlin, Germany) and centrifuged (20 min/450 g/RT/without brake). The PBMC 
interface layer was harvested, diluted in PBS and centrifuged (5 min/400 g/RT). The 
mononuclear cells were washed twice with PBS, and the viability was determined by trypan 
blue exclusion.  
II.7.2 Isolation of CD4+CD45RO+ memory T cells 
CD4+CD45RO+ memory T cells were isolated from the PBMC preparation by negative 
immunomagnetic selection using MACS CD4+T cell isolation kit and MACS CD45RA 
Microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany). The freshly isolated PBMCs 
were mixed with a cocktail of hapten-conjugated antibodies against CD8, CD11b, CD16, 
CD19, CD36 and CD56, and incubated for 10 min at 4°C. After washing, the cells were 
mixed with anti-hapten microbeads and anti-CD45RA microbeads, incubated for 15 min at 
4°C, and washed. The magnetically labeled PBMCs were separated on a column placed in a 
magnetic field. The magnetically labeled cells were retained in the column, whereas the 
unlabeled CD4+CD45RO+ T cells were recovered in the eluat.  
II.7.3 HUVEC 
Human umbilical vein endothelial cells (HUVECs) were obtained from PromoCell 
(Heidelberg, Germany). Culture flasks were coated with collagen G at 40 µg/ml for 30 min at 
37°C, and cells were maintained in Endothelial Cell Growth Medium (PromoCell). Cells were 
used at passage number 1-5. 
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II.7.4 Isolation of mouse aortic endothelial cells 
Mouse aortic endothelial cells were isolated as described (Kreisel et al., 2001). Collagen gels 
were prepared as the substrate for endothelial cell outgrowth from pieces of aortas. 1.5 mg/ml 
rat tail collagen I (Biomol, Plymouth Meeting, PA, USA) in DMEM supplemented with 10% 
(v/v) FCS was mixed on ice with NaOH to final concentration 6.5 mM. This mixture was 
aliquoted into a 24-well plate at 500 µl per well, allowed to gel at 37° for 60 min, and 
equilibrated with complete EC medium (RPMI-1640, 20% (v/v) FCS, 4 µl/l 2-
mercaptoethanol, 25 µg/ml gentamicin, and 50 µg/ml EC growth supplement; BD 
Biosciences) overnight. The medium was aspirated from the collagen gels prior to the 
placement of aortic segments.  
 
Aortas from JAM-A+/+apoE-/- or JAM-A-/-apoE-/- mice were isolated and cleaned from peri-
adventitial fat, cut into rings, opened, and placed endothelial side-down onto the collagen 
gels. After 2 days, complete EC medium was added. After 7-10 days, aortic segments were 
removed and the gel was digested with 0.3% (w/v) collagenase H (Sigma, Deisenhofen, 
Germany). The released cells were passaged into cell culture flasks for cultivation.  
 
II.8 Work with E.coli 
E. coli were cultured in LB medium at 37°C with vigorous shaking. For growth on solid 
media, a bacteria suspension was spread on a LA agar plate or a single bacteria colony was 
inoculated to achieve single colony growth. The LA plates were incubated inverted overnight 
at 37°C. For culturing of bacteria transformed with a plasmid conferring antibiotic resistance, 
growth medium was supplemented with the appropriate antibiotic. For long-term storage of 
bacteria at -80°C, LB medium was supplemented with glycerol to a final concentration of 
15% (v/v). All solutions used for bacteria work were autoclaved or filter-sterilized.  
II.8.1 Bacteria growth medium 
Bacteria growth medium was autoclaved for 20 min at 121°C. LA agar medium was allowed 
to cool to 50°C before addition of antibiotics.  
 
LB medium:  0.5% (w/v) Yeast extract, 1% (w/v) Peptone 140, 1% (w/v) 
NaCl 
LA agar medium: LB medium with 1.4% (w/v) Agar 
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II.8.2 Preparation of chemically competent E. coli 
Chemically competent E. coli were prepared as described by Chung et al., 1989. 100 ml LB 
medium was inoculated with 750 µl overnight culture of E. coli DH5α and grown at 37°C 
with vigorously shaking until the early exponential growth phase (OD600 = 0.4). OD600 was 
measured in a spectrophotometer with pure medium as reference. The culture was centrifuged 
(10 min/3000 g/4°C), and the pellet was resuspended in 10 ml ice-cold TSS buffer. 500 µl 
aliquots were frozen immediately in liquid nitrogen and stored at -80°C. 
 
TSS buffer:  10% (w/v) PEG 8000 (Promega, Madison, WI, USA) 
  5% (v/v) DMSO 
  20 mM MgCl2 
  in 1x LB medium (II.8.1)  
 
II.8.3 Heat-shock transformation of competent E. coli 
100 µl thawed competent E. coli were gently mixed with 5 µl plasmid ligation reaction 
(II.9.6) or 1-5 ng of plasmid DNA, and incubated for 30 min on ice. The bacteria were heat-
shock treated for 90 sec in a 42°C waterbath, and then incubated for 2 min on ice. After 
addition of 900 µl LB medium, the bacteria were incubated for 1 h at 37°C with gently 
shaking. The bacteria were spread on selective LA agar plates and incubated overnight at 
37°C to select for transformed bacteria. 
II.9 Recombinant DNA techniques 
II.9.1 Restriction endonuclease digestion of DNA 
Restriction endonucleases (MBI Fermentas, Ontario, Canada) were used to digest double-
stranded DNA for subcloning and analytical purposes. Restriction endonucleases recognize 
specific palindromic sequences and cleave a phosphodiester bond at each strand at that 
sequence. Staggered cleavage generates sticky ends with complementary 5’ and 3’ ends, 
whereas cleavage in the axis of symmetry results in blunt ends.  
 
Restriction endonuclease digestion of DNA (plasmid or PCR fragment) was done according 
to the manufactures instructions. For subcloning purposes, 1-3 µg DNA were digested with 
10-20 U of restriction enzyme in a volume of 20-40 µl. For analytical purposes, 0.2-1 µg 
DNA were digested with 5-10 U restriction enzyme in a volume of 20 µl. Digests were 
incubated for 1 h at 37°C or as recommended by the supplier. Reaction buffers were supplied 
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by the manufacturer. Enzymes were heat-inactivated at 65°C for 20 min or removed by 
Qiaquick PCR Purification Kit (Qiagen, Hilden, Germany). For digest of DNA with two 
different enzymes requiring different buffers, the DNA was precipitated (II.9.5) after the first 
digest and dissolved in the buffer required for the second digest.  
 
II.9.2 Fill-in of 5’-overhangs to generate blunt ends 
In order to join DNA fragments with non-complementary sticky ends or to join a DNA 
fragment with sticky ends with blunt ended DNA, the 5’ to 3’ polymerase activity of the 
Klenow fragment (New England Biolabs, Ipswich, MA, USA) of DNA Polymerase I was 
used to fill-in 5’ overhangs to generate blunt ends. The DNA fragment with 5’overhangs was 
incubated in a volume of 25-50 µl containing 0.05 mM dNTP, 2-3 U Klenow fragment and 1x 
Klenow buffer supplied by the manufacturer. The fill-in reaction was incubated for 10 min at 
37°C and then the Klenow enzyme was heat-inactivated at 65°C for 20 min.  
 
II.9.3 DNA extraction from agarose gels 
Isolation of DNA fragments after digest (II.9.1) or PCR amplification (II.10.1) was done by 
preparative agarose gel electrophoresis. After separation of DNA fragments by agarose gel 
electrophoresis (II.9.9), the DNA fragment of interest was removed from the gel under UV 
light illumination. The DNA was recovered from the gel slice using the Qiaquick Gel 
Extraction Kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions.  
 
II.9.4 Dephosphorylation of linearized plasmid DNA 
Linearized vector plasmids were dephosphorylated with shrimp alkaline phosphatase (SAP) 
(Roche, Basel, Switzerland) in order to prevent self-ligation of vector ends. SAP catalyzes the 
dephosphorylation of 5’-phosphates from DNA. For dephosphorylation of sticky ends was 
used 1 U SAP pro 1 pmol DNA and the reaction was incubated for 10 min at 37°C, whereas 
blunt ends were incubated for 60 min at 37°C with 1 U SAP pro 0.2 pmol DNA. SAP was 
heat-inactivated at 65°C for 15 min.  
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II.9.5 Precipitation of DNA 
Precipitation of DNA was used to concentrate DNA or to dissolve DNA in another buffer. 
The DNA sample was diluted with 0.1 volume of 3 M sodium acetate, pH 5.2 and 2.5 volume 
96% (v/v) ethanol. After incubation at -20°C for 30 min, the precipitated DNA was 
centrifuged (20 min/20000 g/RT). The pellet was washed with 70% (v/v) ethanol and 
centrifuged (10 min/20000 g/RT). The DNA was air dried for 5 min and dissolved in water or 
the required buffer.  
 
II.9.6 Ligation of DNA fragments 
Ligation of DNA insert into linearized vector plasmid was done with T4 DNA ligase 
(Promega, Madison, WI, USA), which catalyzes the formation of a phosphodiester bond 
between a 5’-phosphate and a 3’-hydroxyl group of two double-stranded DNA fragments with 
either complementary sticky ends or blunt ends. The ligation reaction was performed in a 
volume of 15 µl containing 90 fmol insert DNA, 30 fmol linearized dephosphorylated vector 
plasmid, 1 U T4 DNA ligase and 1x ligation buffer supplied by the manufacturer. The ligation 
reaction was incubated overnight at 16°C. For calculation of required DNA quantities, the 
following equation was used: 
bp 1000
bp in  DNAof size
fmol 3000
 µg 1   DNAfmol   DNAµg ××=  
II.9.7 Miniprep: Small-scale purification of plasmid DNA 
Plasmid DNA was purified from a bacteria culture by alkaline lysis as described by Sambrook 
and Russell, 2001. 1.5 ml overnight culture was centrifuged (1 min/7000 g/RT) and the pellet 
was resuspended in 100 µl buffer 1 (50 mM glucose, 25 mM Tris-HCl pH 8.0, 10 mM EDTA 
pH 8.0, 100 µg/ml RNase A). For lysis of the bacteria, 200 µl of buffer 2 (200 mM NaOH, 
1% (w/v) SDS) was added followed by gently mixing and 5 min incubation at RT. The 
mixture was neutralized by 200 µl ice-cold buffer 3 (3 M potassium acetate, pH 5.5), gently 
mixed, and incubated for 5 min at -20°C. The suspension was centrifuged (20 min/20000 
g/RT) to remove proteins, cell debris and chromosomal DNA. The supernatant with plasmid 
DNA was transferred to a new eppendorf tube mixed with 500 µl isopropanol and centrifuged 
(20 min/20000 g/RT). The pellet with plasmid DNA was washed with 70% (v/v) ethanol, air 
dried and resuspended in 50 µl 10 mM Tris-HCl, pH 8.5. For DNA sequencing (II.9.11),  
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DNA was isolated with the Qiaprep Spin Miniprep Kit (Qiagen, Hilden, Germany) according 
to the manufacturer’s instructions.  
II.9.8 Midiprep and Maxiprep: Large-scale purification of plasmid DNA 
Large-scale purification of plasmid DNA from bacteria overnight culture was performed 
using the Qiagen Plasmid Midi or Maxi Kit (Qiagen, Hilden, Germany) according to the 
manufacturer’s instructions.  
 
II.9.9 Agarose gel electrophoresis 
Separation of DNA fragments from digest (II.9.1) or PCR amplification (II.10.1) was done by 
agarose gel electrophoresis. The negatively charged DNA fragments migrate towards the 
anode in an electric field at a rate determined by the size. DNA samples were diluted with 
DNA loading buffer and separated on a 1-2% (w/v) agarose gel dissolved in TAE 
electrophoresis buffer containing 0.1 µg/ml ethidium bromide. After electrophoresis at 110 V, 
the DNA was visualized on a UV light transilluminator and photographed for documentation.   
 
DNA loading buffer (6x)  30% (v/v) glycerol 
6 mM EDTA 
0.25% (w/v) bromophenol blue  
0.25% (w/v) xylenecyanol  
 
TAE electrophoresis buffer (1x)  40 mM Tris-acetate 
1 mM EDTA  
 
II.9.10 Quantification of DNA and RNA 
DNA and RNA concentration was determined by measuring the absorbance at 260 nm (A260) 
in a spectrophotometer using a quartz cuvette. For double-stranded DNA an A260=1 
corresponds to 50 µg DNA/ml, and for RNA an A260=1 corresponds to 40 µg RNA/ml. The 
absorbance at 280 nm was also measured to estimate DNA and RNA purity. Pure DNA or 
RNA has an A260/A280 ratio of 1.8-2.0 at pH 7.0.  
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II.9.11 Sequencing of DNA 
DNA construct were sequenced to exclude mismatches. DNA sequencing was done by a 
commercial sequencing service (MWG Biotech, Martinsried, Germany) and the sequence data 
were verified on the basis of the corresponding electropherogram.  
 
II.10 Polymerase chain reaction 
II.10.1 Polymerase chain reaction  
Polymerase chain reaction (PCR) was used to amplify specific DNA sequences (Saiki et al., 
1988). In addition, this method  allows the introduction of new cleavage sites for restriction 
endonucleases or other modifications useful for the generation of DNA constructs. Primers 
with specific sequences were commercially synthesized (MWG Biotech, Martinsried, 
Germany). PCR fragments for cloning purposes were amplified with the high fidelity Pfu 
DNA Polymerase (Promega), which minimizes base misinsertions due to a 3’→5’ 
exonuclease proofreading activity. Annealing temperature was optimized for each primer set 
based on the primer melting temperature.  
 
PCR reaction:  50-200 ng template DNA   
1x PCR reaction buffer  
0.5 µM forward primer  
0.5 µM reverse primer   
200 µM each of dNTPs (dATP, dCTP, dGTP, dTTP) 
 1.3 U Taq DNA polymerase or Pfu DNA polymerase (Promega) 
  H2O to final volume of 50 µl 
 
PCR program:  Initial denaturation  95°C, 2 min 
  Denaturation  95°C, 45 sec  
  Annealing  50-65°C, 30 sec        25-35 cycles 
  Extension  72°C, 1-2 min 
  Final extension 72°C, 5 min 
   
II.10.2 Quantitative Real-Time PCR 
Total RNA of whole carotids from wild-type or apoE-/- mice was isolated with the RNeasy 
Mini Kit (Qiagen) and digestion of genomic DNA using the RNase-free DNase set (Qiagen) 
according to the manufacturer’s protocol. RNA concentration was determined (II.9.10) and 
RNA was reverse transcribed to cDNA using oligo-dT primers and the Sensiscript RT Kit 
(Qiagen).  
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The reverse transcription reaction was incubated for 1 h at 37°C: 
cDNA synthesis:  2 µl 10x RT buffer 
  2 µl dNTP mix (5 mM each) 
  2 µl 10 µM oligo-dT primer (MWG Biotech) 
  1 µl RNase inhibitor (10 U/µl) 
  1 µl Sensiscript reverse transcriptase 
  50 ng template RNA 
  H2O to final volume 20 µl 
JAM-A expression was analyzed by real-time PCR. Standard curves were made for JAM-A 
and GAPDH using the corresponding cDNA cloned into the vector pBluescript (Stratagene, 
La Jolla, CA, USA). Target mRNA was quantified according to the standard curve and 
normalized to levels of GAPDH.  
 
Real-Time PCR reaction: 5 µl cDNA or standard 
  10 µl 2x QuantiTect SYBR Green PCR Master Mix (Qiagen) 
  forward primer to final concentration 0.5 µM 
  reverse primer to final concentration 0.5 µM 
  RNase free water to final volume 20 µl 
 
Real-Time PCR Program: Initial activation step  95°C, 15 min 
  Denaturation  94°C, 15 sec  
  Annealing  55°C, 30 sec            45 cycles 
  Extension  72°C, 30 sec 
  Plate read 
  Melting curve from 55°C to 95°C 
 
 
Primers for Real-Time PCR: 
mouse JAM-A forward 5’-AGCCAGATCACAGCTCCCTA-3’ 
mouse JAM-A reverse 5’-TGGATGGAGGTACAAGCACA-3’ 
mouse GAPDH forward 5’-CACTCAAGATTGTCAGC-3’ 
mouse GAPDH reverse 5’-CCACAGCCTTGGCAGC-3’ 
 
II.11 Generation of stably transfected cell lines 
II.11.1 Generation of cDNA construct for I domain-deleted human αL 
A cDNA construct for human αL lacking the I domain (N129-K304) was generated by PCR 
using wild-type αL cDNA subcloned into the expression vector pAprM8 (Klickstein et al., 
1996) as template. A cDNA fragment encoding for amino acid (aa) residues 1-128 of αL 
including a 3’BglII cloning site was amplified by PCR using the forward primer (5’-
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CAGTACATCAATGGGCGTGGATAG-3’) and reverse primer (5’-
CGTTCGTAGATCTTGCCCTTGATACATTC-3’), which introduces the underlined BglII 
site. The wild-type αL in pAprM8 was digested with HindIII and BglII to remove a fragment 
encoding for aa residue 1-304 of αL, and instead, the PCR fragment encoding for aa residue 1-
128 was inserted as a HindIII/BglII fragment. Finally, the cDNAs encoding wild-type αL and 
the I domain-deficient mutant αL∆I were subcloned into the expression vector pcDNA3 
(Invitrogen, Karlsruhe, Germany), which confers resistance to G418, and the constructs were 
sequenced (II.9.11) to exclude mismatches. 
 
II.11.2 J-β2.7 transfectants 
Stable transfection of αL-deficient Jurkat J-β2.7 cells was done by electroporation as described 
(Weber et al., 1997a). 107 cells growing in log phase were transfected with 10 µg of plasmid 
DNA (pcDNA3, pcDNA3/αL, or pcDNA3/αL∆I) using the gene-pulser II electroporator (Bio-
Rad) with the parameters 260 V, 975 µF, 200 Ω. After 48 hours under nonselective culture 
conditions, transfected cells were selected with G418 sulfate (Calbiochem) at 800 µg/ml. 
G418-resistent cells were subcloned by limiting dilution in 96-well plates with round bottom 
and clones were analyzed by flow cytometry (II.12) with the mAb G25.2 (II.4.1) to assess the 
level of LFA-1 expression. Clones with comparable levels of LFA-1 expression were used in 
all studies.  
 
II.11.3 CHO transfectants 
A CHO cell line with human JAM-A surface expression was generated by stable transfection 
of wild-type CHO cells. 107 CHO cells growing in log phase (passaged the day before 
transfection) were transfected with 10 µg plasmid DNA (pcDNA3 or pcDNA3/JAM-A) using 
the gene-pulser II electroporator (Bio-Rad) with the parameters 260 V, 975 µF, 200 Ω. After 
48 hours under nonselective culture conditions, transfected cells were selected with G418 
sulfate at 1000 µg/ml. G418-resistent cells were subcloned by limiting dilution in 96-well 
plates with flat bottom and clones were analyzed by flow cytometry (II.12) with the mAb 
M.Ab.F11 against human JAM-A.  
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II.12 Flow cytometry 
Flow cytometry analysis allows to measure optical and fluorescence characteristics of single 
cells passing an argon laser. Measurements of forward scatter (representing cell size) and side 
scatter (representing internal complexity) was used to determine cell numbers in 
transmigration assays (II.14.4). Measurement of fluorescence intensity allows to determine 
protein expression using fluorescence labeled Abs. The results were displayed as histograms 
showing the logarithmic distribution of the measured fluorescence intensity.  
 
For flow cytometry analysis, 1⋅105 cells were resuspended in PBS/0.5% (w/v) BSA with 
specific Ab or IgG isotype control (10 µg/ml) and incubated for 30 min on ice. After washing, 
the cells were incubated with FITC-conjugated secondary Ab (10 µg/ml) for 30 min on ice. 
The cells were washed and analyzed immediately by flow cytometry in a FACSCalibur (BD 
Biosciences, San Jose, CA, USA). In order to measure intracellular fluorescence intensity 
(e.g. von Willebrand Factor expression), cells were permeabilized with 0.1% (v/v) Triton X-
100 in PBS for 5 min before incubation with Ab.   
 
II.13 Protein analysis 
II.13.1 Purification of soluble JAM-A.Fc and ICAM-1.Fc protein 
Soluble JAM-A.Fc and ICAM-1.Fc protein was stably expressed in CHO cells as chimeric 
proteins containing the extracellular part of human JAM-A or ICAM-1 fused to the Fc portion 
of human IgG1 using cDNA constructs available in the laboratory. Soluble chimeric protein 
was secreted into the selective culture medium. The culture medium was supplemented with 
ultra-low IgG FCS (Gibco BRL, Karlsruhe, Germany) to minimize IgG contaminations. The 
CHO culture medium was collected and supplemented with 10 mM Tris-HCl, pH 7.5, 1 mM 
EDTA, 0.01% (w/v) sodium azide, 1 protease inhibitor cocktail tablet (Roche, Basel, 
Switzerland), and passed through a 0.2 µm filter. 
 
Soluble JAM-A.Fc or ICAM-1.Fc protein was purified from the CHO cell supernatant by 
Protein A affinity chromatography. The CHO supernatant was loaded onto a HiTrap Protein 
A column, fast-flow, 1 ml volume (Amersham Biosciences, Uppsala, Sweden) using a 
peristaltic pump. The column was connected to a fast protein liquid chromatography (FPLC) 
system (UPC-900 and P-920, Amersham Biosciences), washed with PBS, and eluted with 50 
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mM glycine, pH 3.0. Elution fractions of 1.0 ml were collected and neutralized with 1M Tris-
HCl, pH 9.0 until final pH 7.0. Protein concentration was determined by Bio-Rad DC assay 
(Bio-Rad) using BSA as standard. Purified protein was dialyzed overnight at 4°C against 150 
mM NaCl, 10 mM HEPES, pH 7.4. Correct expression and protein purity was determined by 
SDS-PAGE and western blot analysis (see II.13.4) or Coomassie blue staining (II.13.5).  
 
II.13.2 Whole cell lysates 
Mammalian cells were harvested and washed with ice-cold PBS. 2⋅106 cells were resuspended 
in 200 µl ice-cold lysis buffer and homogenized by passing 10 times through a 20G (Ø 0.9 
mm) needle fitted to a 1 ml syringe. The protein concentration was determined by DC Protein 
Assay (Bio-Rad, Hercules, CA, USA) using BSA as standard curve. The cell lysates were 
diluted with SDS-PAGE sample buffer and heated for 5 min at 95°C. The cell lysates were 
analyzed by SDS-PAGE or stored at -80°C.  
 
Lysis buffer   50 mM Tris-HCl, pH 6.8  
2% (w/v) SDS  
1 mM PMSF  
   10 mM DTT (for reducing conditions) 
 
SDS-PAGE sample buffer (5x) 200 mM Tris-HCl, pH 6.8 
   30% (v/v) glycerol 
5% (w/v) SDS 
   0.1% (w/v) bromophenol blue  
     
II.13.3 SDS-PAGE 
Whole cell lysates or purified protein were analyzed by SDS-polyacrylamide gel 
electrophoresis (PAGE). SDS binds to polypeptides resulting in a negative charge directly 
proportional to protein size. Protein samples were first concentrated in a stacking gel before 
migrating into the resolving gel. Electrophoresis was carried out at 200 V. The resolving gel 
was further analyzed by western blotting (II.13.4) or coomassie blue staining (II.13.5).  
 
Resolving gel   10% (w/v) acrylamide/Bis 
   375 mM Tris-HCl, pH 8.8 
   0.1% (w/v) SDS 
   0.1% (w/v) ammonium persulfate 
   0.1% (v/v) TEMED  
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Stacking gel   5% (w/v) acrylamide/Bis 
   125 mM Tris-HCl, pH 6.8 
   0.1% (w/v) SDS 
   0.1% (w/v) ammonium persulfate 
   0.1% (v/v) TEMED 
 
Electrophoresis buffer (10x)  250 mM Tris base 
   1.92 M glycine  
   1% (w/v) SDS 
 
II.13.4 Western blot analysis 
By western blotting analysis the separated proteins from a SDS-PAGE (II.13.3) were 
transferred to a nitrocellulose membrane and detected using specific primary Abs and HRP-
conjugated secondary Ab. The proteins were transferred to the nitrocellulose membrane 
(Hybond-ECL, Amersham Biosciences, Uppsala, Sweden), at 76 V for 1 hour in ice-cold 
blotting buffer. Nonspecific binding sites on the membrane were blocked with 5% (w/v) non-
fat milk in TBS/0.05% (v/v) Tween for 1 hour at RT. The membrane was incubated with 
primary Ab diluted in blocking buffer for 1 hour at RT or overnight at 4°C. After washing, the 
membrane was incubated with HRP-conjugated secondary Ab diluted in TBS/0.05% (v/v) 
Tween for 1 hour at RT. Bound HRP was detected with the chemiluminescent substrate ECL 
(Pierce, Rockford, IL, USA) and exposure to an autoradiografic film (Kodak, Rochester, NY, 
USA).  
 
Blotting buffer (1x)  25 mM Tris base 
   192 mM glycine  
   10% (v/v) methanol  
   0.005% (w/v) SDS  
 
II.13.5 Coomassie blue staining 
Coomassie blue staining of polyacrylamide gels allows the detection of proteins separated by 
SDS-PAGE (II.13.3). Gels were fixed for 5 min, stained for 10-60 min, and destained for 2 h.  
 
Fixation/Destain solution  30% (v/v) methanol 
   10% (v/v) acetic acid 
 
Coomassie blue solution  30% (v/v) methanol 
   10% (v/v) acetic acid 
   0.1% (w/v) Coomassie blue R250 
   0.2% (w/v) Coomassie blue G250 
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II.13.6 Solid-phase binding assay 
The interactions between soluble JAM-A.Fc and immobilized locked-open LFA-1 I domain 
was analyzed in a solid-phase binding assay. 96-well plates (Costar, Cambridge, MA, USA) 
were coated with locked-open LFA-1 I domain (2 µg/ml) or BSA (2 µg/ml) as control, in 100 
mM sodium carbonate buffer, pH 9.0, 10 mM Mg2+, and blocked with 3% (w/v) BSA, 10 mM 
Mg2+. Binding of sJAM-A.Fc (0-2 µM) to immobilized I domain was performed in a total 
volume of 50 µl of TBS, 0.5% (w/v) BSA supplemented with either 2 mM Mg2+ or 2 mM 
EDTA. After washing, bound JAM-A.Fc was detected with HRP-conjugated anti-human Fc 
Ab. Bound Ab was quantified using the tetramethylbenzidine (TMB) substrate reagent kit 
(BD Biosciences, San Jose, CA, USA). The reaction was stopped with 1 M H2SO4 and the 
absorption was measured at 450 nm using a microplate reader. Nonspecific binding to BSA-
coated wells was substracted to calculate specific binding. Normalized data were fitted to a 
simplified single site binding model using nonlinear regression as described (Woska et al., 
1996).  
  
II.14 Cell assays 
II.14.1 Static adhesion to immobilized JAM-A.Fc or ICAM-1.Fc 
The adhesion of cells to immobilized protein was analyzed in a static adhesion assay carried 
out in 96-well plates. Cells in suspension were labeled with the fluorescence dye BCECF/AM 
and incubated in wells coated with the respective adhesion target protein. Nonadherent cells 
were removed by flick washes and fluorescence of remaining cells adherent to immobilized 
protein was determined with a fluorescence plate reader. 
 
Soluble JAM-A.Fc or ICAM-1.Fc (II.13.1) at 15 µg/ml was immobilized overnight at 4°C in 
96-well maxisorp plates (NUNC, Roskilde, Denmark) coated with Fc-specific anti-human 
IgG (Sigma, Deisenhofen, Germany) at 20 µg/ml. Nonspecific sites were blocked with 0.5% 
(w/v) BSA in PBS for 1 h at RT. Jurkat cells (II.6.1) or J-β2.7 transfectants (II.11.2) to be 
analyzed for adhesion were fluorescence labeled with BCECF/AM (1 µg/ml) at a density of 
106 cells/ml for 25 min at 37°C and washed. Some cells were pretreated with TS1/22 mAb 
(10 µg/ml), BIRT377 (10 µM), sJAM-A.Fc (15 µg/ml) or sCD30.Fc (15 µg/ml) for 20 min at 
RT. Cells (1.5⋅105 cells/well) were allowed to adhere in wells for 30 min at 37°C in the 
absence or presence of PMA (100 ng/ml) or 3 mM Mg2+/1 mM EGTA.  
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Nonadherent cells were removed by flick washes. Wells were repeatedly filled with warm 
HHMC buffer (II.2) and emptied by rigorously inverting the plate. Input and adherent cells 
were measured in a fluorescence plate reader with excitation at 485 nm and emission at 535 
nm. Adhesion was expressed as the percentage of input cells. Background binding to anti-
human IgG was negligible and substracted.  
 
Adhesion of Monocytic Mono Mac 6 cells (II.6.3) to immobilized JAM-A.Fc was performed 
accordingly with the following modifications: monocytes were preincubated for 20 min with 
5% (v/v) heat-inactivated human serum to block Fc receptors and 0.5⋅105 cells/well were 
used. For adhesion of Mono Mac 6 cells to HUVEC monolayers, confluent HUVEC 
monolayers in 96-well plates were costimulated overnight with TNF-α (100 U/ml) and IFN-γ 
(200 U/ml).  
 
II.14.2 Static adhesion to locked-open I domain 
Adhesion of CHO transfectants (II.11.3) to locked-open αL I domain was analyzed in 
adhesion assays in 96-well plates. Locked-open αL I domain or BSA as control was 
immobilized in 96-well NUNC Maxisorp plates at 15 µg/ml in 10 mM Tris pH 9.0 overnight 
at 4°C. After blocking with 0.5% (w/v) BSA some wells were preincubated for 20 min at RT 
with BIRT377 (10 µM) or 10 mM DTT and washed.  BCECF/AM labeled CHO transfectants 
in HHMC buffer (II.2) were allowed to adhere for 30 min at 37°C. Nonadherent cells were 
removed by flick washes as described above (II.14.1). Fluorescence of input and adherent 
cells were measured with a fluorescence plate reader, and adhesion was expressed as the 
percentage of input cells. Background binding to BSA was negligible and substracted.  
 
II.14.3 Cell arrest under laminar flow conditions 
A laminar flow assay was used to investigate cell arrest under physiological flow conditions. 
Confluent HUVEC monolayers were costimulated overnight with TNF-α (100 U/ml) and 
IFN-γ (200 U/ml). SDF-1α (500 ng/ml) was immobilized on the HUVECs for 30 min prior to 
the experiment. CD4+CD45RO+ T cells (II.7.2) resuspended in HHMC/0.5% BSA (w/v) were 
preincubated with HP2/1 (anti-VLA-4), TS1/22 (anti-LFA-1), hIgG control, hJAM-A Ab, 
sJAM-A.Fc, or sCD30.Fc for 20 min at 37°C. Antibodies, isotype controls, and soluble Fc-
proteins were used at 10 µg/ml unless indicated otherwise. T cells (1⋅106 cells/ml) were 
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perfused at 1.5 dyn/cm2 over endothelial monolayers inserted in a parallel wall flow chamber. 
Cell arrest was directly visualized and documented by video microscopy. After a 4 min flow 
equilibration period, cell arrest or cells undergoing shape change, spreading, and subsequent 
transmigration was quantified in multiple 0.25 mm2 fields. Results were expressed as 
cells/mm2.  
 
II.14.4 Transmigration assay (chemotaxis) 
Transmigration of leukocytes across an endothelial monolayer toward a chemokine gradient 
was investigated using Transwell® filter inserts (Costar, Cambridge, MA, USA). HUVECs 
were grown to confluence on collagenized filter inserts with a membrane diameter of 6.5 mm 
and 5.0 µm pore size. CD4+CD45RO+ memory T cells (II.7.2) were incubated with TS1/22 
(anti-LFA-1), hIgG control, hJAM-A Ab, sJAM-A.Fc, or sCD30.Fc for 20 min at 37°C. 
Antibodies, isotype controls, and soluble Fc-proteins were used at 10 µg/ml unless indicated 
otherwise. T cells (0.5⋅106 cells/well) in RPMI-1640/0.5% (w/v) BSA were allowed to 
transmigrate across HUVEC monolayers toward SDF-1α (500 ng/ml) in the bottom chamber 
for 90 min. Input and migrated cells were counted by flow cytometry (II.12).  
 
II.14.5 Ex vivo perfusion of murine carotid arteries 
Monocytic cell accumulation on early atherosclerotic endothelium was investigated using an 
ex vivo perfusion assay of murine carotid arteries. After anesthesia of apoE-/- mice, the carotid 
bifurcation including the common carotid artery (CCA), internal (ICA) and external (ECA) 
branches was exposed. Branches were ligated with sutures and a polyethylene catheter was 
inserted through an incision of the CCA distal to a ligation. The artery was perfused with 
MOPS-buffered physiological salt solution with 0.5% (w/v) human serum albumin using a 
syringe pump. Outflow was enabled by punctures in the ECA and ICA. The vessel was cut 
distal to sutures and transferred onto a microscope stage (immersion objective 20x, Olympus 
BX51) superfused at 37°C with bicarbonate-buffered saline. CD4+CD45RO+ T cells (0.5⋅106 
cells/ml) labeled with calcein/AM were preincubated with HP2/1 (anti–VLA-4), TS1/22 (anti-
LFA-1), sJAM-A.Fc, or sCD30.Fc in MOPS buffer (II.2) at 37°C and perfused at a flow rate 
of 3 µl/min. Antibodies, isotype controls, and soluble Fc-proteins were used at 10 µg/ml 
unless indicated otherwise. Adhesive interactions with the atherosclerotic vessel wall were 
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recorded using stroboscopic epifluorescence illumination (Drelloscop 250, Drello, Germany). 
Cells not moving for more than 30 s were defined as adherent.  
 
II.15 Immunofluorescence 
Endothelial cell expression of JAM-A in carotid arteries of mice was analyzed with double 
immunofluorescence staining for JAM-A and the endothelial cell marker PECAM-1. 
C57BL/6 apoE-/- mice (Taconic M&B, Ry, Denmark) were fed an atherogenic diet containing 
21% (w/v) fat, 0.15% (w/v) cholesterol and 19.5% (w/v) casein (Altromin, Lage, Germany) 
for 6 weeks. After intraperitoneal anesthesia with ketamine/xylazine, carotid arteries of wild-
type or apoE-/- mice were exposed, fixed with 4% (w/v) paraformaldehyde and embedded in 
paraffin. 5-µm sections were stained for murine JAM-A using mAb H2O2-106-7-4 (4 µg/ml), 
QuickKit and Vector Red Substrate (Vector Laboratories, Burlingame, CA, USA). Double 
staining for endothelial cells was performed with anti–PECAM-1 (2 µg/ml) followed by a 
secondary FITC-conjugated anti-goat Ab. Isotype controls were used at equal concentrations. 
Images were recorded using a Leica DMLB microscope and CCD camera.  
 
II.16 Statistical analysis 
Statistical analysis was performed using Prism 4.0 (GraphPad Software). Data represent mean 
± SEM and were analyzed by 2-tailed Student t test or 1-way ANOVA followed by Newman-
Keuls post-test when appropriate. Differences with at least P<0.05 were considered as 
statistical significant. 
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III  Results 
 
III.1 Role of LFA-1 I domain in interactions with JAM-A 
The interaction between the integrin LFA-1 and its ligand JAM-A is mediated by the 
membrane-proximal Ig-like domain 2 of JAM-A (Ostermann et al., 2002). In contrast, the 
location of the JAM-A binding domain in LFA-1 has not been identified. As the I domain in 
the αL subunit of LFA-1 has been implicated as the principal ligand-binding domain for 
interactions between LFA-1 and the ICAMs (Randi and Hogg, 1994; Yalamanchili et al., 
2000), the focus of this thesis was the investigation if the I domain of LFA-1 is also the 
ligand-binding domain for interactions with JAM-A.  
III.1.1 Expression of I domain-deleted LFA-1 in Jurkat J-β2.7 T cells 
The I domain of the αL subunit of LFA-1 is not essential for folding, heterodimerization with 
the β2 subunit, or LFA-1 surface expression (Huang and Springer, 1997; Yalamanchili et al., 
2000). This allows investigation of the function of the LFA I domain by expression of an I 
domain-deleted mutant of the αL subunit of LFA-1. Therefore, a cDNA construct was 
generated (II.11.1), which lacked the sequence corresponding to amino acid N129-K304 of 
the αL subunit (Fig. 3-1A). This I-less αL subunit was termed αL∆I. The length of the deletion 
was based on the crystal structure of αL (Qu and Leahy, 1995) and no linker sequence was 
added since the N and C termini of the I domain are in close proximity (Springer, 1997).  
 
The cDNA constructs for αL∆I and wild-type (wt) αL were used for stable transfection of 
human J-β2.7 T lymphoid cells. The cell line J-β2.7 is a mutant Jurkat T cell line generated by 
chemical mutagenesis which lacks LFA-1 surface expression due to a deficiency in αL 
(CD11a) expression (Weber et al., 1997b). J-β2.7 cells retain a functional β2 subunit, which is 
only translocated to the cell surface upon heterodimerization with transfected αL (Leitinger 
and Hogg, 2000; Weber et al., 1997b). This cell line therefore provided an ideal system to 
investigate the role of the LFA-1 I domain in the interactions with JAM-A. After stable 
transfection and single cell cloning, clones with comparable surface expression of αL∆I and 
wt αL were selected by flow cytometry using the mAb G25.2 specific for the αL subunit of 
human LFA-1 (Fig. III-1B). The mAb G25.2, which recognizes an epitope outside the I 
domain, reacted equally well with the transfectants expressing αL∆I or wt αL. In contrast, the I 
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domain-specific mAb TS1/22 bound to transfectants expressing wt αL but not αL∆I, 
confirming the deletion of the I domain in αL∆I. Furthermore, equivalent expression of 
JAM-A in transfectants was found by flow cytometry using a mAb specific for human 
JAM-A (Fig. III-1B).  
 
 
 
Figure III-1. Schematic illustration of wild-type αL and I domain deleted αL (II.11.1) and flow cytometry 
based analysis (II.12) of J-β2.7 transfectants (II.11.2).  
(A) Schematic illustration of the wild-type αL (wt αL) and the I domain-deleted αL (αL∆I) subunits. Shown in 
gray are the β-sheets W1-W7 in the predicted β-propeller domain. The I domain of αL is inserted between β-
sheets W2 and W3. TM represents the transmembrane region. In αL∆I the deletion includes amino acid residues 
N129-K304. (B) Expression of JAM-A and αL epitopes on J-β2.7 clones stably transfected with wild-type αL (wt 
αL), I domain-deleted αL (αL∆I) (II.11.1) or vector alone. Cells were stained with mAbs G25.2 (anti-αL, non-I 
domain specific), TS1/22 (anti-αL, I domain specific), M.Ab.F11 (anti-human JAM-A) or isotype controls (10 
µg/ml), followed by FITC-conjugated goat anti-mouse IgG and analysis by flow cytometry. Filled histograms, 
isotype control; open histograms, mAbs G25.2, TS1/22 or M.Ab.F11. Data shown are representative histograms 
of three experiments. 
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III.1.2 Expression and purification of soluble JAM-A.Fc and ICAM-1.Fc protein 
In order to analyze the interactions between J-β2.7 transfectants and JAM-A, soluble 
JAM-A.Fc protein was generated. Soluble JAM-A.Fc fusion protein was stably expressed in 
Chinese hamster ovary (CHO) cells as a chimeric protein containing the extracellular part of 
human JAM-A fused to the Fc part of human IgG1. The signal peptide of JAM-A directed 
JAM-A.Fc to the plasmamembrane of transfected CHO cells, where JAM-A.Fc was secreted 
into the cell culture medium due to the lack of a transmembrane domain. JAM-A.Fc protein 
was purified from the CHO cell supernatant by protein A affinity chromatography. After 
elution from the protein A column (Fig. III-2), elution fractions with high protein 
concentration were pooled, purified on a MonoQ column, and dialyzed against 150 mM NaCl, 
10 mM HEPES, pH 7.4. Purity and correct expression of JAM-A.Fc protein was verified by 
SDS-PAGE, coomassie blue staining (Fig. III-4A) and western blot analysis (Fig. III-4B). The 
JAM-A.Fc protein yield from one liter of CHO cell culture supernatant was 2.8 mg 
recombinant protein.  
 
 
Figure III-2. Purification of JAM-A.Fc soluble protein from CHO cell culture supernatant (II.13.1).  
Protein A affinity purification elution profile of JAM-A.Fc protein. One liter of CHO cell culture supernatant 
was loaded on a l ml HiTrap protein A fast-flow column and eluted with a gradient of 0-50 mM glycine pH 3.0 
at a flow rate of 0.5 ml/min. In blue is shown the JAM-A.Fc elution peak, in green the gradient of 0-50 mM 
glycine pH 3.0, in brown the conductivity, and in red the elution fractions (A1-A13).  
 
 
 
 
III  Results 42
Figure III-3. Purification of ICAM-1.Fc soluble protein from CHO cell culture supernatant (II.13.1).  
Protein A affinity purification elution profile of ICAM-1.Fc protein. 500 ml CHO cell culture supernatant were 
loaded on a l ml HiTrap protein A fast-flow column and eluted with a gradient of 0-50 mM glycine pH 3.0 at a 
flow rate of 0.5 ml/min. In blue is shown the ICAM-1.Fc elution peak, in green the gradient of 0-50 mM glycine 
pH 3.0, in brown the conductivity, and in red the elution fractions (A1-A12).  
 
In order to study interactions between J-β2.7 transfectants and ICAM-1, soluble ICAM-1.Fc 
protein was generated accordingly. ICAM-1.Fc chimeric protein containing the extracellular 
part of human ICAM-1 fused to the Fc part of human IgG1 was expressed in CHO cells and 
purified by protein A chromatography. Nonspecific binding to the column was removed by 
injection of 2 ml 0.5 M NaCl in PBS. After elution from the protein A column (Fig. III-3), 
elution fractions with high protein concentration were pooled and dialyzed against 150 mM 
NaCl, 10 mM HEPES, pH 7.4. The purity and correct expression of ICAM-1.Fc soluble 
protein was verified by SDS-PAGE, Coomassie blue staining (Fig. III-4A) and western blot 
analysis (Fig. III-4C). The ICAM-1.Fc protein yield from 500 ml of CHO cell culture 
supernatant was 3.1 mg recombinant protein.  
 
JAM-A and ICAM-1 were expressed in the mammalian CHO cells to obtain glycosylation 
patterns resembling that of human cells. CHO cells are suitable for protein expression because 
they are fast growing cells and easy to culture. In order to avoid contaminations with IgG 
from the culture medium, the medium for protein expression was supplemented with a ultra-
low IgG serum.  
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Figure III-4. SDS-PAGE (II.13.3) and Western blot analysis (II.13.4) of affinity purified JAM-A.Fc and 
ICAM-1.Fc (II.13.1).  
(A) Protein samples were separated by SDS-PAGE under reducing conditions and the gel was stained with 
Coomassie Blue. Staining revealed distinct bands corresponding to JAM-A.Fc (60 kDa) and ICAM-1.Fc (120 
kDa) and no protein impurities could be detected. Lane 1: SeeBlue Plus2 Molecular Marker (Invitrogen); Lane 2: 
purified JAM-A.Fc protein (2 µg); Lane 3: purified ICAM-1.Fc protein (2 µg). (B) Western blot analysis of 
purified JAM-A.Fc protein (250 ng). Proteins were separated by SDS-PAGE under reducing conditions and 
transferred to nitrocellulose membrane. JAM-A.Fc was detected using rabbit anti-human JAM-A pAb 246 
(II.4.1) at 1 µg/ml. Lane 1: purified JAM-A.Fc protein. (C) Western blot analysis of purified ICAM-1.Fc protein 
(250 ng) under reducing conditions. ICAM-1.Fc was detected using mouse anti-human ICAM-1 mAb G-5 
(II.4.1) at 0.5 µg/ml. Lane 1: purified ICAM-1.Fc protein. Protein molecular weight markers are indicated in 
kDa. Representive gel and blots are shown.  
 
 
 
III.1.3 The I domain of LFA-1 is necessary for leukocyte adhesion to immobilized 
JAM-A.Fc  
Adhesion of J-β2.7 transfectants to JAM-A.Fc was analyzed in adhesion assays carried out in 
96 well plates. As control, the adhesion of J-β2.7 transfectants to ICAM-1.Fc was analyzed. 
ICAM-1.Fc or JAM-A.Fc protein was immobilized in 96-well microtiter plates precoated 
with Fc-specific anti-human IgG. Incubation of fluorescence-labeled J-β2.7 transfectants in 
suspension in wells with immobilized ICAM-1.Fc or JAM-A.Fc protein allowed the 
measurement of cell adhesion under static conditions by fluorescence spectrometry. 
Nonadherent cells were removed by extensive washing and adherent cells were quantified by 
measurement of fluorescence intensity. LFA-1 integrin on the surface of J-β2.7 transfectants 
was activated by either stimulation of intracellular signal transduction pathways with phorbol-
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12-myristate-13-acetate (PMA) or by extracellular integrin activation with Mg2+/EGTA. The 
stimulation with Mg2+ in combination with chelation of Ca2+ with EGTA, leads to high 
affinity states of LFA-1 (Dransfield et al., 1992; Stewart et al., 1996). After stimulation with 
PMA or Mg2+/EGTA, only the J-β2.7 transfectants expressing wt LFA-1 showed binding to 
ICAM-1.Fc, whereas those transfectants expressing I domain deleted LFA-1 or vector 
controls showed almost no binding (∼95% reduction) to ICAM-1.Fc (Fig. III-5A). These 
results are in accordance with findings that the I domain of LFA-1 is the principal ligand 
binding domain for the interaction with ICAM-1 (Randi and Hogg, 1994; Yalamanchili et al., 
2000).  
Figure III-5. Static adhesion (II.14.1) of J-β2.7 transfectants (II.11.2) to immobilized ICAM-1.Fc or JAM-
A.Fc (II.13.1).  
Effect of αL I domain deletion on adhesion of J-β2.7 transfectants to ICAM-1.Fc and JAM-A.Fc. J-β2.7 
transfectants expressing wild-type αL or the I domain-deleted mutant αL∆I were allowed to adhere to 
immobilized ICAM-1.Fc (A) or JAM-A.Fc (B). Cells (1.5⋅105 cells/well) were stimulated with 3 mM Mg2+/1 
mM EGTA or PMA (100 ng/ml) for 30 min. Nonadherent cells were removed by flick wash and adhesion was 
measured as percentage of input cells. Data represent mean ± SEM of at least three independent experiments 
done in triplicate. 
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To determine whether the I domain of LFA-1 is required for binding to JAM-A, the adhesion 
of J-β2.7 transfectants to immobilized JAM-A.Fc was analyzed. As seen on ICAM-1.Fc, the 
wt LFA-1 transfectants showed firm adhesion to immobilized JAM-A.Fc both after 
stimulation with PMA or Mg2+/EGTA, whereas transfectants expressing LFA-1 without the I 
domain or vector controls showed very reduced (85-95% reduction) adhesion to JAM-A.Fc 
(Fig. III-5B). Since these results have implied that the I domain of LFA-1 is required for 
binding of LFA-1 to the ligand JAM-A, the involvement of the LFA-1 I domain in the 
interactions with JAM-A was further analyzed.  
 
III.1.4 LFA-1 binding to JAM-A is inhibited by an I domain-directed LFA-1 antagonist 
or blocking mAb 
To further analyze the role of the LFA-1 I domain in the interaction with JAM-A, leukocyte 
adhesion to immobilized JAM-A.Fc was studied in the presence of the LFA-1 I domain 
specific mAb TS1/22 (Sanchez-Madrid et al., 1982) or the small molecule LFA-1 antagonist 
BIRT377, both known to inhibit LFA-1 binding to ICAM-1 (Kelly et al., 1999; Petruzzelli et 
al., 1998). BIRT377 blocks interactions of LFA-1 and ICAM-1 by binding to an epitope in 
the I domain comprising amino acid P281 and stabilizing the I domain in a closed low-affinity 
conformation (Last-Barney et al., 2001).  
Figure III-6. Flow cytometry analysis (II.12) for LFA-1 surface expression on Jurkat cells (II.6.1).  
Cells were stained with isotype control, mAb TS1/22 (anti-αL) (A), or mAb TS1/18 (anti-β2) (B), followed by 
FITC-conjugated goat anti-mouse IgG and analysis by flow cytometry. Filled histograms, isotype controls; open 
histograms, mAb TS1/22 or mAb TS1/18. FL1-H represents the logarithmic fluorescence intensity. Data shown 
are representive histograms. 
 
The cell line Jurkat is a human T lymphoid cell line. Like other lymphocytes, Jurkat cells 
express LFA-1 integrin on the cell surface as seen with flow cytometry analysis using 
antibodies specific for the αL or β2 subunit of human LFA-1 (Fig. III-6A and III-6B).  
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Incubation of fluorescence-labeled Jurkat cells with immobilized ICAM-1.Fc or JAM-A.Fc 
allowed to study the binding of LFA-1 on the surface of Jurkat cells to immobilized protein 
under different conditions. Treatment of Jurkat cells with mAb TS1/22 or the antagonist 
BIRT377 almost completely inhibited their adhesion to immobilized ICAM-1.Fc after 
stimulation with PMA or Mg2+/EGTA (Fig. III-7A). These result are consistent with the 
notion that TS1/22 and BIRT377 prevent the interaction of LFA-1 with ICAM-1 by 
interfering with the I domain of LFA-1.  
Figure III-7. Static adhesion (II.14.1) of Jurkat cells to immobilized ICAM-1.Fc or JAM-A.Fc.  
Adhesion of Jurkat cells to immobilized ICAM-1.Fc (A) or JAM-A.Fc (B) after stimulation with 3 mM Mg2+/1 
mM EGTA or PMA (100 ng/ml). Some cells were preincubated with BIRT377 (10 µM) or TS1/22 (10 µg/ml) 
for 30 min before adding to the plate (1.5⋅105 cells/well). Nonadherent cells were removed by flick wash and 
adhesion was measured as percentage of input cells. Preincubation with DMSO or isotype control had no 
significant effect on binding (data not shown). Data represent mean ± SEM of at least three independent 
experiments done in triplicate.  
 
Treatment of Jurkat cells with mAb TS1/22 or the antagonist BIRT377 also reduced cell 
adhesion to immobilized JAM-A.Fc following activation of LFA-1 by PMA or Mg2+/EGTA 
to levels observed for unstimulated cells (Fig. III-7B). Treatment with isotype control Ab 
(mouse IgG1) or DMSO (solvent of BIRT377) had no effect on cell adhesion (data not 
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shown). Thus, blocking I domain function with mAb TS1/22 or the small molecule LFA-1 
antagonist BIRT377 inhibits the interaction between LFA-1 and JAM-A, further 
substantiating that the I domain of LFA-1 is crucial for binding to JAM-A.  
 
 
To analyze whether interactions of JAM-A and LFA-1 also occur in leukocytes subtypes 
other than lymphocytes, the adhesion of monocytes to immobilized JAM-A.Fc was studied. 
Mono Mac 6 cells are human monocytic cells, which have cell surface expression of LFA-1 
receptors as seen with flow cytometry analysis using antibodies against the αL and β2 subunit 
of human LFA-1 (Fig. III-8A and III-8B). Since monocytic cells are also expressing high 
amount of Fc-receptors on the cell surface (Ravetch and Kinet, 1991), Fc-receptors were 
blocked with human serum before adhesion of monocytic cells to exclude binding to the Fc 
part of JAM-A.Fc.  
 
Figure III-8. Flow cytometry analysis (II.12) for LFA-1 surface expression on Mono Mac 6 cells (II.6.3).  
Cells were stained with isotype control, mAb TS1/22 (anti-αL) (A), or mAb TS1/18 (anti-β2) (B), followed by 
FITC-conjugated goat anti-mouse IgG and analysis by flow cytometry. Filled histograms, isotype controls; open 
histograms, mAb TS1/22 or mAb TS1/18. FL1-H represents the logarithmic fluorescence intensity. Data shown 
are representive histograms.  
 
 
As seen with the Jurkat T cells, Mono Mac 6 cells showed adhesion to JAM-A.Fc after 
stimulation with PMA or Mg2+/EGTA (Fig. III-9). As revealed by a very reduced (78-93% 
reduction) adhesion by addition of mAb TS1/22 or antagonist BIRT377, the binding to JAM-
A.Fc was mediated by the LFA-1 I domain.  
 
 
αL β2
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Figure III-9. Static adhesion (II.14.1) of Mono Mac 6 cells (II.6.3) to immobilized JAM-A.Fc.  
Adhesion of monocytic Mono Mac 6 cells to JAM-A.Fc after stimulation with 3 mM Mg2+/1 mM EGTA or 
PMA (100 ng/ml). Some cells were preincubated with BIRT377 (10 µM) or TS1/22 (10 µg/ml) for 30 min 
before adding to the plate (0.5⋅105 cells/well). Nonadherent cells were removed by flick wash and adhesion was 
measured as percentage of input cells. Preincubation with DMSO (solvent of BIRT377) or isotype control had 
no significant effect on binding (data not shown). Data represent mean ± SEM of at least three separate 
experiments done in triplicate. 
 
 
III.1.5 Recombinant isolated locked-open LFA-1 I domain binds JAM-A 
LFA-1 on resting leukocytes does not bind spontaneously to its ligands, but needs to assume a 
high-affinity conformation, also called an open conformation, as a result of stimulation. It has 
previously been shown, that the introduction of a disulfide bond by the double mutation 
K287C and K294C could lock the αL I domain in the open high-affinity conformation 
(Shimaoka et al., 2001). The recombinant LFA-1 I domain locked in the open conformation 
could support binding to its ligand ICAM-1 (Shimaoka et al., 2001). It was therefore 
hypothesized that the recombinant LFA-1 I domain locked in the open high-affinity 
conformation is sufficient for binding to JAM-A.  
 
Chinese hamster ovary (CHO) cells are adherent cells, which grow to confluent monolayers. 
Since CHO cells do not express endogenous JAM-A, this enabled expression of human 
JAM-A in CHO cells and analysis of cell adhesion to αL I domain. CHO cells were stably 
transfected with human JAM-A (CHO/JAM-A) or vector alone (CHO/vector). After single 
cell cloning, clones were analyzed for surface expression of human JAM-A by flow 
cytometry. Using an antibody specific for human JAM-A, expression of JAM-A was detected 
on CHO/JAM-A transfectants but not on CHO/vector transfectants (Fig. III-10A and III-10B). 
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Expression of human JAM-A in CHO/JAM-A transfectants, but not in CHO/vector 
transfectants, was also confirmed by immunoblotting using a mAb specific for human JAM-A 
(Fig. III-11). The constitutive expression of JAM-A did not result in changes in growth or 
viability of transfected CHO cells (data not shown).  
Figure III-10. Flow cytometry analysis (II.12) for surface expression of JAM-A on CHO transfectants 
(II.11.3)  
JAM-A expression on CHO/vector transfectants (A) and CHO/JAM-A transfectants (B). Cells were stained with 
isotype control (filled histograms) or anti-human JAM-A mAb (open histograms), followed by FITC-conjugated 
goat anti-mouse IgG and analysis by flow cytometry. FL1-H represents the logarithmic fluorescence intensity. 
Data shown are representive histograms of three experiments. 
Figure III-11. Western blot analysis (II.13.4) of whole cell lysates (II.13.2) from CHO transfectants 
(II.11.3). 
Whole cell lysates from CHO/vector (lane 1) and CHO/JAM-A (lane 2) transfectants were separated by SDS-
PAGE under reduced conditions and transferred to nitrocellulose membrane. JAM-A was detected using mouse 
anti-human JAM-A, clone 43 (BD Biosciences) at 0.5 µg/ml followed by HRP conjugated anti-mouse IgG. 
Protein molecular weight markers are indicated in kDa. Representive blot is shown.  
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Recombinant locked-open LFA-1 I domain was immobilized in 96-well microtiter plates. 
Incubation of fluorescence-labeled CHO transfectants in suspension in wells with 
immobilized locked-open αL I domain protein, allowed the analysis of cell adhesion. CHO 
transfectants expressing JAM-A showed substantial binding to immobilized locked-open I 
domain. In contrast, CHO/vector transfectants did not bind to locked-open I domain (Fig. III-
12). 
 
Figure III-12. Static adhesion (II.14.2) of CHO transfectants (II.11.3) to immobilized locked-open αL I 
domain.  
CHO transfectants expressing JAM-A bind to locked-open αL I domain. Adhesion of CHO/vector and 
CHO/JAM-A transfectants to immobilized locked-open αL I domain. Data represent mean ± SEM of at least 
three separate experiments done in triplicate. 
 
 
The LFA-1 antagonist BIRT377 binds to the closed low-affinity conformation of the αL I 
domain, and prevents conversion to the open high-affinity conformation (Last-Barney et al., 
2001). The binding of CHO/JAM-A transfectants to locked-open αL I domain was not 
inhibited by preincubation of locked-open αL I domain with the LFA-1 antagonist BIRT377 
(Fig. III-13), showing that BIRT377 does not bind to the mutated locked-open I domain. In 
contrast, reduction of the disulfide bond in locked-open I domain with DTT, reduced binding 
of CHO/JAM-A transfectants to background levels (Fig. III-13). The adhesion assays with 
CHO transfectants revealed that the isolated LFA-1 I domain is sufficient to support binding 
to JAM-A and that this binding was specifically mediated by the open high-affinity 
conformation of LFA-1.  
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Figure III-13. Static adhesion (II.14.2) of CHO/JAM-A transfectants (II.11.3) to immobilized locked-open 
αL I domain.  
Some wells were preincubated with BIRT377 (10 µM) or 10 mM DTT. Data represent mean ± SEM of at least 
three independent experiments done in triplicate. 
 
 
III.1.6 Biochemical evidence for a direct interaction of JAM-A with the LFA-1 I domain 
Since the functional results from cell-based adhesion studies suggested a direct molecular 
interaction between JAM-A and the LFA-1 I domain, a solid-phase binding assay with 
recombinant and purified proteins was performed to demonstrate a direct molecular 
interaction between JAM-A and the I domain of LFA-1. The LFA-1 I domain locked in the 
open high-affinity conformation was immobilized in 96-well plates. After blocking of non-
specific binding sites with 3% (w/v) BSA, soluble JAM-A.Fc protein was added to the wells. 
Soluble JAM-A.Fc protein bound to the high-affinity form of the I domain was detected by 
HRP-conjugated anti-human Fc-specific Ab (Fig. III-14A). The experiments indeed 
confirmed that soluble JAM-A.Fc directly bound to locked-open I domain in the presence of 2 
mM Mg2+. The binding was dose-dependent and saturable with a dissociation constant (Kd) of 
∼0.5 µM, as indicated by fitting of the binding curve (Fig. III-14B). The binding of JAM-A.Fc 
to locked-open I domain was cation dependent, since binding could be almost completely 
inhibited by addition of EDTA (Fig. III-14B).  
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Figure III-14. Solid-phase binding assay (II.13.6) for binding of recombinant JAM-A.Fc (II.13.1) to 
immobilized locked-open LFA-1 I domain.  
(A) Principle of the solid-phase binding assay. (B) Dose-dependent binding of recombinant JAM-A.Fc to 
immobilized locked-open LFA-1 I domain. Nonspecific binding to BSA-coated wells was substracted to 
calculate specific binding. Specific binding of JAM-A.Fc at indicated concentrations was analyzed in the 
presence of either 2 mM Mg2+ or 2 mM EDTA. Bound JAM-A.Fc was detected with HRP-conjugated anti-
human Fc Ab. The fraction of bound ligand is given as mean ± SEM of three to five separate experiments. Solid 
lines represents a nonlinear fit of the data.  
 
 
 
III.2 Inhibition of distinct steps of mononuclear cell recruitment by 
soluble JAM-A 
III.2.1 Inhibition of mononuclear cell adhesion with soluble JAM-A.Fc  
JAM-A expressed on endothelial cells contributes to the inflammatory recruitment of 
mononuclear cells by engagement of its integrin receptor LFA-1 (Ostermann et al., 2002). 
The involvement of JAM-A in distinct steps of mononuclear cell recruitment was therefore 
investigated using soluble JAM-A.Fc (sJAM-A.Fc) protein as a competitive inhibitor.  
 
ICAM-1.Fc protein was immobilized in 96-well microtiter plates precoated with Fc-specific 
anti-human IgG. Incubation of fluorescence-labeled Jurkat cells in suspension in wells with 
immobilized ICAM-1.Fc protein allowed the measurement of cell adhesion under static 
conditions by fluorescence spectrometry. LFA-1 integrin on the surface of Jurkat cells was 
activated by stimulation with PMA. Pre-incubation of Jurkat cells with sJAM-A.Fc protein 
inhibited specific LFA-1/ICAM-1 interactions, leading to a significant decrease in T cell 
adhesion on ICAM-1.Fc (58.8 ± 6.4% of control, n=5; P<0.01) (Fig. III-15A).  
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Figure III-15. Static adhesion (II.14.1) of PMA-stimulated Jurkat T cells to immobilized ICAM-1.Fc.  
(A) Jurkat cells were pretreated with LFA-1 mAb, hIgG Ab, sJAM-A.Fc (15 µg/ml) or sCD30.Fc (15 µg/ml). 
(B) Jurkat cells were pretreated with sJAM-A.Fc at concentrations ranging from 1 to 30 µg/ml. Adhesion is 
expressed as percentage of control. Data are mean ± SEM of at least 4 independent experiments performed in 
triplicate. **P<0.01 vs control.  
 
Treatment of Jurkat cells with sJAM-A.Fc at concentrations ranging from 1 to 30 µg/ml 
further revealed that the interference with T cell adhesion in stasis was dose-dependent (Fig. 
III-15B). As control, Jurkat cells were treated with human IgG (hIgG) Ab or soluble CD30.Fc 
fusion protein, which binds to the unrelated membrane protein CD30R on mononuclear cells. 
Treatment of Jurkat cells with hIgG or sCD30.Fc did not interfere with cell adhesion to 
ICAM-1.Fc (Fig. III-15A).  
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Similarly, the influence of sJAM-A.Fc treatment on monocytic Mono Mac 6 cell adhesion on 
HUVEC monolayers was studied. HUVEC monolayers were costimulated with the 
proinflammatory cytokines TNF-α and IFN-γ to redistribute JAM-A from cell junctions to the 
apical surface of endothelial cells (Ozaki et al., 1999).  
 
Some Mono Mac 6 cells were treated with a blocking mAb specific for VLA-4 to exclude 
VLA-4/VCAM-1 interactions and study LFA-1-mediated adhesion only. The VLA-4-
independent adhesion of monocytic Mono Mac 6 cells on HUVECs was significantly 
decreased by treatment with sJAM-A.Fc as compared to VLA-4 blocking alone (54.1 ± 1.7, 
n=4; P<0.05 versus VLA-4 mAb). Treatment with sCD30.Fc had no significant effect on cell 
adhesion (Fig. III-16). 
 
Figure III-16. Static adhesion (II.14.1) of monocytic Mono Mac 6 cells to TNF-α/IFN-γ-costimulated 
HUVEC monolayers.  
Mono Mac 6 cells were treated with a blocking Ab against VLA-4, sJAM-A.Fc, or VLA-4 Ab in combination 
with sJAM-A.Fc or sCD30.Fc. Data are mean ± SEM of at least 4 independent experiments performed in 
triplicate. *P<0.05 vs VLA-4 mAb. 
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III.2.2 Inhibition of T cell arrest under flow conditions by soluble JAM-A.Fc 
Given that physiological shear flow affects adhesion of mononuclear cells to activated 
endothelium (Cinamon et al., 2001), the effect of sJAM-A.Fc treatment on CD4+CD45RO+ 
memory T cell arrest on inflamed endothelium in flow was analyzed. Confluent HUVEC 
monolayers were costimulated with TNF-α and IFN-γ to redistribute JAM-A from cell 
junctions to the apical surface, and monolayers were inserted in a parallel wall flow chamber. 
CD4+CD45RO+ memory T cells isolated from venous blood of healthy volunteers by negative 
immunomagnetic selection were perfused at 1.5 dyn/cm2, which resembles physiological 
shear flow. In order to analyze LFA-1-mediated arrest only, CD4+CD45RO+ memory T cell 
were treated with a blocking mAb specific for VLA-4 to exclude interactions with VCAM-1 
or other VLA-4 ligands expressed on activated endothelium. To trigger cell arrest, the 
chemokine SDF-1α was immobilized on endothelium.  
 
Immobilization of SDF-1α on HUVEC monolayers resulted in more than 2-fold increase in 
memory T cell arrest. The increase in cell arrest was LFA-1-dependent as shown with the 
blocking mAb TS1/22 specific for the αL subunit of LFA-1. Treatment of memory T cells 
with TS1/22 reduced arrest to levels as seen without SDF-1α (Fig. III-17A). Pre-incubation of 
CD4+CD45RO+ T cells with sJAM-A.Fc significantly reduced their VLA-4-independent 
arrest on inflamed endothelium under flow (50.4 ± 4.2 of control, n=4; P<0.01). This 
inhibition of cell arrest was more marked than inhibition seen with a blocking Ab specific for 
JAM-A (Fig. III-17A). Treatment of memory T cells with the irrelevant Fc fusion protein 
sCD30.Fc had no significant effect on cell arrest (Fig. III-17A). Treatment of memory T cells 
with sJAM-A.Fc at concentrations ranging from 1 to 30 µg/ml revealed a dose-dependency of 
its inhibitory effect (Fig. III-17B).  
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Figure III-17. SDF-1α-triggered arrest under physiological shear flow (II.14.3) of CD4+CD45RO+ memory 
T cells (II.7.2) on inflamed endothelium.  
(A) CD4+CD45RO+ T cells were pre-treated with a LFA-1 mAb (TS1/22), human IgG control, JAM-A Ab, 
sJAM-A.Fc (10 µg/ml), or sCD30.Fc (10 µg/ml). (B) Dose-dependent inhibition of CD4+CD45RO+ memory T 
cell arrest by sJAM-A.Fc is shown for concentrations ranging from 1 to 30 µg/ml. T cells were pretreated with a 
blocking mAb against VLA-4 to exclude interactions with VCAM-1 or other VLA-4 ligands. Control without 
SDF-1α (w/o SDF-1α). Data are given as mean ± SEM of 4 independent experiments (A) or 1 out of 4 
representative experiments is shown (B). Data is expressed as percentage of control. *P<0.05 vs control, 
**P<0.01 vs control.  
 
 
 
 
 
w/
o S
DF
-1
co
ntr
ol
LF
A-
1 m
Ab
hIg
G 
co
ntr
ol
JA
M-
A 
pA
b
sJ
AM
-A
.Fc
sC
D3
0.F
c
0
25
50
75
100
125
**
*
**
0 10 20 30
0
25
50
75
100
concentration sJAM-A.Fc [µg/mL]
C
D
4+
C
D
45
R
O
+
T 
ce
ll 
ar
re
st
on
 H
U
VE
C
s 
(%
 o
f c
on
tr
ol
)
A
B
C
D
4+
C
D
45
R
O
+
T 
ce
ll 
ar
re
st
on
 H
U
VE
C
s 
(%
 o
f c
on
tr
ol
)
C
D
4+
C
D
45
R
O
+
T 
ce
ll 
ar
re
st
on
 H
U
VE
C
s 
(%
 o
f c
on
tr
ol
)
C
D
4+
C
D
45
R
O
+
T 
ce
ll 
ar
re
st
on
 H
U
VE
C
s 
(%
 o
f c
on
tr
ol
)
III  Results 57
III.2.3 Transendothelial migration of memory T cells is inhibited by soluble JAM-A.Fc 
To further investigate the influence of sJAM-A.Fc on LFA-1-mediated steps of mononuclear 
cell recruitment, transendothelial chemotaxis assays were performed. HUVECs were grown to 
confluent monolayers on transwell filter membranes with 0.5 µm pore size. CD4+CD45RO+ 
memory T cells, isolated from venous blood of healthy volunteers by negative 
immunomagnetic selection, were allowed to transmigrate across the HUVEC monolayers 
towards the chemokine SDF-1α. Memory T cells express the SDF-1α receptor CXCR4 (Bleul 
et al., 1996a) and migrate toward the chemokine SDF-1α (Bleul et al., 1996b). 
Figure III-18. Transendothelial chemotaxis (II.14.4) of CD4+CD45RO+ memory T cells (II.7.2) toward 
SDF-1α in transwell filter assays.  
CD4+CD45RO+ memory T cells were pretreated with a LFA-1 mAb, JAM-A mAb, sJAM-A.Fc protein, hIgG 
Ab, or irrelevant Fc-fusion protein sCD30.Fc. Control without SDF-1α (w/o SDF-1α). Data are mean ± SEM of 
at least 4 independent experiments performed in duplicate. Data are expressed as percentage of control. *P<0.05 
vs control, **P<0.01 vs control. 
 
SDF-1α induced a 15-fold increase in transendothelial migration of memory T cells, which 
was largely mediated by LFA-1 as shown by inhibition of transmigration with a blocking 
mAb specific for LFA-1 (Fig. III-18). Pre-incubation of memory T cells with sJAM-A.Fc 
(47.6 ± 10.6% of control, n=4; P<0.01) or a pAb specific for JAM-A (71.0 ± 4.0% of control, 
n=4; P<0.05) significantly inhibited transendothelial migration toward SDF-1α. As control, 
memory T cells were pre-incubated with hIgG Ab or CD30.Fc, which had no significant 
effect on migration (Fig. III-18).  
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III.3 Involvement of JAM-A in atherogenic recruitment of 
mononuclear cells  
To explore the role of JAM-A in atherosclerosis, the expression of JAM-A on early 
atherogenic endothelium was investigated. To study early atherogenic endothelium, carotid 
arteries from apolipoprotein E-deficient  (apoE-/-) mice were used. ApoE is involved in 
removing excess cholesterol from the blood and is therefore important for maintaining normal 
levels of cholesterol. ApoE-/- mice fed an atherogenic diet develop early stages of 
atherosclerosis (without manifest lesions) within 6 weeks. 
 
III.3.1 Real-time RT-PCR analysis of JAM-A expression in carotid arteries from mice 
The expression of JAM-A in carotid arteries from apoE-/- mice fed an atherogenic diet for 6 
weeks and wild-type mice was compared by real-time polymerase chain reaction (PCR) 
analysis. Total RNA of whole carotid arteries was isolated, reverse transcribed to cDNA by 
reverse transcription PCR (RT-PCR), and analyzed by real-time PCR with specific primers 
against murine JAM-A and murine GAPDH (Glyseraldehyde-3-phosphate dehydrogenase). 
JAM-A mRNA expression was quantified using a standard curve and normalized to levels of 
GAPDH. The real-time PCR analysis showed a 2.6-fold increase of JAM-A mRNA 
transcripts in atherosclerotic carotid arteries of apoE-/- mice as compared with carotid arteries 
of wild-type mice (Fig. III-19). 
 
Figure III-19. Quantitative real-time reverse-transcription polymerase chain reaction analysis (II.10.2) of 
total RNA isolated from carotid arteries from wild-type mice or apoE-/- mice fed an atherogenic diet.  
JAM-A mRNA expression was normalized to levels of GAPDH mRNA. *P<0.05 (n=3) 
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III.3.2 Immunofluorescence staining analysis of JAM-A expression on atherosclerotic 
endothelium of carotid arteries from mice 
In order to analyze if the upregulation of JAM-A mRNA templates reflects a specific 
upregulation of JAM-A in endothelial cells, JAM-A expression was analyzed by 
immunofluorescence staining of carotid arteries from wild-type or apoE-/- mice. Carotid 
arteries of apoE-/- mice fed an atherogenic diet for 6 weeks or wild-type mice were fixed and 
embedded in paraffin. Double staining of 5-µm sections with an Ab specific for murine 
JAM-A and an Ab specific for the endothelial cell marker PECAM-1 allowed to analyze the 
expression of JAM-A in endothelial cells. Compared with the endothelial marker PECAM-1, 
the staining for JAM-A was only faintly visible on the endothelium of carotid arteries in wild-
type mice (Fig. III-20). In contrast, a distinct expression of JAM-A was found on the luminal 
surface formed by atherosclerotic endothelium of the carotid artery in apoE-/- mice (Fig. III-
20), which may reflect upregulation and apical redistribution of JAM-A after endothelial 
activation. Discrete staining for JAM-A was also detected in smooth muscle cells. No staining 
was seen with IgG isotype controls (data not shown).  
 
 
Figure III-20. Double immunofluorescence staining (II.15) for JAM-A (red) and the endothelial cell 
marker PECAM-1 (green) in carotid arteries of mice.  
Endothelial JAM-A expression in murine carotid arteries. Double immunofluorescence staining for the 
endothelial cell marker PECAM-1 (green) and JAM-A (red) in carotid arteries of wild-type or apoE-/- mice after 
atherogenic diet for 6 weeks. Expression of JAM-A in endothelial cells is seen as yellow in the overlay. No 
staining was seen with IgG isotype controls (data not shown). Scale bar, 20 µm.  
wild-type
apoE-/-
PECAM-1 JAM-A Merge
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III.3.3 Mononuclear cell recruitment to atherosclerotic endothelium is blocked by 
soluble JAM-A.Fc  
To gain insights into the functional relevance of JAM-A expression in early atherogenic 
recruitment of mononuclear cells, the accumulation of mononuclear cells in ex vivo perfused 
carotid arteries of mice was investigated. It was first tested if this could be analyzed in a 
heterologous system, where human monocytes were treated with soluble human JAM-A and 
allowed to adhere to murine endothelium. Adhesion experiments with human Mono Mac 6 
cells perfused under physiological flow conditions over murine SVEC endothelial 
monolayers, indeed showed that human monocytes are able to adhere to murine endothelium 
(Fig. III-21A).  
 
Furthermore, treatment of human monocytes with soluble human JAM-A.Fc or treatment of 
murine endothelium with a blocking Ab specific for murine JAM-A could interfere with this 
heterologous interaction. Relevant IgG isotype controls had no significant effect on monocyte 
arrest (Fig. III-21A). Human monocytes were also able to bind murine endothelium in ex vivo 
perfusion assays in carotid arteries of TNF-α-treated wild-type mice (Fig. III-21B). This 
heterologous interaction could be blocked by treatment of human monocytes with a blocking 
mAb specific for human VLA-4. The VLA-4-independent accumulation of human monocytes 
could be inhibited by treatment of murine endothelium with an Ab specific for murine JAM-A 
(Fig. III-21B). Treatment with isotype IgG control had no significant effect on monocyte 
adhesion (data not shown).   
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Figure III-21. Adhesion under flow conditions (II.14.3) of human monocytes on murine endothelium. 
Pretreatment of human Mono Mac 6 cells with sJAM-A.Fc (10 µg/ml) and pretreatment of murine SVEC 
monolayers with mJAM-A mAb (10 µg/ml) inhibited monocyte adhesion on TNF-α/IFN-γ–costimulated SVECs 
at 1.5 dyn/cm2. hIgG and isotype controls had no significant effect (A). VLA-4–independent accumulation of 
human Mono Mac 6 cells (treated with blocking VLA-4 mAb) in ex vivo perfused carotid arteries of TNF-α–
treated wild-type mice was inhibited by mJAM-A mAb (10 µg/ml) (B). Data are mean ± SEM of 3-4 
independent experiments and expressed as percentage of control.  *P<0.05 vs VLA-4 mAb, **P<0.01 vs control.   
 
Since this heterologous system had proven very applicable to study mononuclear cell 
recruitment, it was used to analyze the involvement of JAM-A in early atherogenic 
recruitment of mononuclear cells. Carotid arteries of apoE-/- mice fed an atherogenic diet for 6 
weeks were perfused ex vivo with fluorescence-labeled human Mono Mac 6 cells. Adhesive 
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interactions with the atherosclerotic vessel wall were recorded using fluorescence 
illumination. Monocytic cell accumulation on early atherosclerotic endothelium has been 
described to dependent on interactions of VLA-4 integrin with endothelial VCAM-1 
(Cybulsky et al., 2001). This was also found in this system, where treatment of Mono Mac 6 
cells with a blocking mAb against VLA-4 inhibited adhesion to murine endothelium (42.2 ± 
4.7% of control, n=5; P<0.01 versus control) (Fig. III-22A).  
 
Figure III-22. Accumulation of monocytic Mono Mac 6 cells in ex vivo perfused (II.14.5) carotid arteries of 
apoE-/- mice.  
Pretreatment with sJAM-A.Fc but not with irrelevant sCD30.Fc impaired cumulative arrest of monocytic Mono 
Mac 6 cells on atherosclerotic endothelium at a flow rate of 3 µl/min when VLA-4 receptors were blocked with 
an inhibitory mAb. Firm arrest was determined after 8 minutes (A) or at indicated time points (B). Data are mean 
± SEM (n=5) expressed as percentage of control. **P<0.01 vs control or VLA-4 mAb, as indicated. 
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With the dominant contribution of VLA-4, pretreatment of monocytic cells with soluble 
JAM-A.Fc alone did not impede their accumulation on early atherosclerotic endothelium 
(96.3 ± 9.2% of control, n=5). However, combined pretreatment of monocytes with blocking 
mAb specific for VLA-4 and soluble JAM-A.Fc further enhanced the inhibition of monocytic 
cell accumulation on early atherosclerotic endothelium (15.9 ± 4.0% of control, n=5; P<0.01 
versus VLA-4 mAb) (Fig. III-22A).  
 
This inhibition was evident throughout the time course of monocyte accumulation (Fig. III-
22B). As control, Mono Mac 6 cells were treated with VLA-4 mAb in combination with 
sCD30.Fc, which did not significantly change accumulation from treatment with VLA-4 mAb 
alone (Fig. III-22A). Using a combination of blocking mAbs to VLA-4 and LFA-1, the 
inhibition was equivalent to the combination of VLA-4 mAb and sJAM-A.Fc, thus indicating 
that the effect of sJAM-A.Fc was likely caused by interference with LFA-1 (Fig. III-22A).  
 
Since blockade of VLA-4 had revealed a LFA-1-mediated contribution of JAM-A to 
monocyte accumulation on atherosclerotic endothelium, which could be inhibited with 
soluble JAM-A.Fc, it was analyzed if this is also found for T cell accumulation on 
atherosclerotic endothelium. Human CD4+CD45RO+ memory T cells were isolated from 
venous blood of healthy volunteers by negative immunomagnetic selection. Carotid arteries of 
apoE-/- mice fed an atherogenic diet for 6 weeks were perfused ex vivo with fluorescence-
labeled human memory T cells. There was indeed observed a similar effect for accumulation 
of memory T cells on atherosclerotic endothelium. While treatment of memory T cells with 
soluble JAM-A.Fc alone had no significant effect (80.9 ± 7.8% of control, n=4), the VLA-4-
independent arrest could be inhibited with soluble JAM-A.Fc (6.2 ± 2.5% of control, n=4; 
P<0.01 versus VLA-4 mAb) (Fig. III-23).  
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Figure III-23. Accumulation of CD4+CD45RO+ memory T cells in ex vivo perfused (II.14.5) carotid 
arteries of apoE-/- mice.  
Treatment of memory T cells with sJAM-A.Fc inhibited the VLA-4-independent arrest on atherosclerotic 
endothelium. Firm arrest was determined after 8 minutes. Data are mean ± SEM (n=4) expressed as percentage 
of control. **P<0.01 vs control or VLA-4 mAb, as indicated. 
 
 
Treatment with irrelevant Fc-fusion protein sCD30.Fc had no significant effect on memory T 
cell arrest (Fig III-23). Thus, blockade of VLA-4 revealed a LFA-1-mediated contribution of 
JAM-A to mononuclear cell arrest on atherosclerotic endothelium that can be inhibited with 
soluble JAM-A.Fc.  
 
III.4 Role of endothelial JAM-A in mononuclear cell adhesion and 
transmigration 
III.4.1 Isolation of JAM-A-deficient mouse aortic endothelial cells 
To explore the role of endothelial JAM-A in leukocyte adhesion and transmigration, aortic 
endothelial cells from JAM-A-deficient mice were isolated. In contrast to using blocking 
antibodies or soluble proteins, this method more directly targets the role of JAM-A in a 
specific cell type. Aortas from JAM-A+/+apoE-/- or JAM-A-/-apoE-/- mice were isolated, cut 
into rings, opened, and placed endothelial side-down onto collagen gels. After two days, cells 
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started migrating from the margins of the aortic segments and into the collagen gels (Fig. III-
24A). Over the next 3-5 days, an increased outgrowth of these cells was observed (Fig. III-
24B). After one week, the aortic segments were removed and the collagen gels were digested 
with collagenase. The released cells were passaged into cell culture flasks for cultivation and 
characterization.  
 
 
Figure III-24. Isolation of JAM-A-deficient mouse aortic endothelial cells (II.7.4). Outgrowth of endothelial 
cells (EC) from mouse aortic segments (AS) into collagen gels after 2 days (A) and 4 days (B).  
 
 
Early passage cells (P2-P5) were analyzed for expression of the endothelial cell marker von 
Willebrand Factor (vWF). After permeabilization, the cells were stained with an Ab specific 
for vWF followed by a FITC-conjugated secondary Ab and analysis by flow cytometry. Both 
JAM-A+/+apoE-/- and JAM-A-/-apoE-/- cells showed expression of vWF with more than 95% of 
the cells being positive (Fig. III-25). Furthermore, equivalent expression of ICAM-1 and 
VCAM-1 in JAM-A+/+apoE-/- and JAM-A-/-apoE-/- cells was found by flow cytometry 
analysis. Finally, an Ab specific for murine JAM-A confirmed the lack of JAM-A expression 
in JAM-A-/-apoE-/- cells (Fig. III-25).  
A B
AS
EC EC
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Figure III-25. Flow cytometry analysis (II.12) of JAM-A+/+apoE-/- and JAM-A-/-apoE-/- mouse aortic 
endothelial cells (II.7.4).  
Cells were stained with specific Abs (10 µg/ml) against vWF, ICAM-1, VCAM-1, or JAM-A, followed by 
FITC-conjugated secondary Ab and analysis by flow cytometry. Filled histograms, isotype control; open 
histograms, vWF, ICAM-1, VCAM-1 or JAM-A. FL1-H represents the logarithmic fluorescence intensity. Data 
shown are representative histograms of three independent experiments.   
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III.4.2 JAM-A-deficient endothelial cells support less monocyte arrest and 
transmigration  
In order to analyze the role of endothelial JAM-A in mononuclear cell adhesion, aortic 
endothelial cells from JAM-A+/+apoE-/- or JAM-A-/-apoE-/- mice were grown to confluent 
monolayers and stimulated with TNF-α and IFN-γ. Human monocytic Mono Mac 6 cells 
were perfused at physiological shear flow and cell adhesion was counted in multiple fields 
using video microscopy. Compared with JAM+/+ monolayers, JAM-A-/- monolayers supported 
significant less monocyte adhesion (Fig. III-26). Also the amount of firmly adherent 
monocytes undergoing shape change, spreading and subsequent transmigration was directly 
visualized by video microscopy. Again, JAM-A-/- monolayers supported significant less 
transmigration of monocytes as compared with JAM-A+/+ monolayers (Fig. III-26).  
 
Figure III-26. Adhesion and transmigration of human monocytes on murine endothelium under flow 
conditions (II.14.3).  
Confluent aortic JAM-A+/+apoE-/- or JAM-A-/-apoE-/- endothelial cell monolayers were stimulated with TNF-α 
and IFN-γ overnight. Mono Mac 6 cells (II.6.3) were perfused at 1.5 dyn/cm2. After 4 minutes, firmly adherent 
and transmigrated cells were counted in multiple fields recorded by video microscopy. Data represent mean ± 
SEM (n=3). *P<0.05 vs JAM-A+/+apoE-/-.  
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IV  Discussion 
 
IV.1 Role of the LFA-1 I domain in interactions with JAM-A  
The interactions between the integrin LFA-1 and its ligand JAM-A has been found to depend 
on the membrane-proximal Ig-like domain D2 of JAM-A (Ostermann et al., 2002). Until now, 
the location of the JAM-A binding domain in LFA-1 has not been defined. In this study, the 
role of the LFA-1 I domain for the functional interactions of LFA-1 with the ligand JAM-A 
was analyzed. It was shown that the I domain of LFA-1 is sufficient and required for the 
functional interaction of LFA-1 with its ligand JAM-A.  
 
The Jurkat J-β2.7 T-cell line is deficient in LFA-1 (αLβ2) expression due to chemical 
mutagenesis of the cd11a gene encoding for the αL subunit of LFA-1 (Weber et al., 1997b). 
This provided the possibility for expression of an I domain-deleted mutant of LFA-1 in J-β2.7 
T cells. Surface expression of wt LFA-1 and I domain-deleted LFA-1 on J-β2.7 transfectants 
was verified by flow cytometry analysis (Fig. III-1). In order to investigate cell adhesion of 
J-β2.7 transfectants to immobilized LFA-1 ligands, ICAM-1.Fc and JAM-A.Fc protein was 
purified. Proteins were expressed in CHO cells as chimeric proteins containing the 
extracellular part of human ICAM-1 or human JAM-A fused to the Fc part of human IgG1. 
The Fc tag allowed purification by protein A affinity chromatography and subsequent 
immobilization for adhesion assays using Fc-specific anti-human IgG antibody.  
 
The binding of J-β2.7 transfectants to immobilized ICAM-1 was tested in adhesion assays. 
Upon integrin activation with PMA or Mg2+/EGTA, only transfectants expressing wt LFA-1 
but not those expressing I domain-deleted LFA-1 or vector controls showed substantial 
binding to ICAM-1 (Fig. III-5A). These results are in accordance with other findings showing 
that the I domain of LFA-1 is the major ligand binding domain for the interactions with 
ICAM-1 (Leitinger and Hogg, 2000; Randi and Hogg, 1994; Yalamanchili et al., 2000).  
 
To determine whether the I domain of LFA-1 is required for binding to JAM-A, the adhesion 
of J-β2.7 transfectants to immobilized JAM-A.Fc was analyzed. As seen on ICAM-1.Fc, 
J-β2.7 transfectants expressing wt LFA-1 showed firm adhesion to JAM-A both after 
stimulation with PMA or Mg2+/EGTA, whereas transfectants expressing LFA-1 without the I 
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domain or vector control did not adhere to immobilized JAM-A.Fc (Fig. III-5B). These results 
imply that the I domain of LFA-1 is required for binding to JAM-A. Since the J-β2.7 
transfectants showed equivalent expression of JAM-A (Fig. III-1B), the adhesion of J-β2.7 
transfectants to JAM-A.Fc could not be mediated by JAM-A homophilic interactions between 
JAM-A expressed on J-β2.7 transfectants and immobilized JAM-A.Fc protein. The 
involvement of the LFA-1 I domain in the interactions between LFA-1 and JAM-A was 
further analyzed in adhesion assays using the blocking mAb TS1/22 specific for the LFA-1 I 
domain or the LFA-1 I domain antagonist BIRT377. The interactions between LFA-1 and 
ICAM-1 have previously been shown to be inhibited by TS1/22 (Petruzzelli et al., 1998) and 
BIRT377 (Kelly et al., 1999), and this was confirmed in this study. As seen on ICAM-1.Fc, 
the adhesion of T cells or monocytes to immobilized JAM-A.Fc was inhibited by the mAb 
TS1/22 or the antagonist BIRT377 (Fig. III-7B). These results further substantiate that the I 
domain of LFA-1 is crucial for binding to JAM-A. In contrast, the Mac-1 I domain is not 
crucial for ligand binding activity to all ligands. I domain deleted Mac-1 can bind at reduced 
levels to some Mac-1 ligands including factor X and iC3b (Yalamanchili et al., 2000). Thus, 
the I domain is not crucial for binding of all I domain containing integrins to all ligands.  
 
These results have shown that the I domain of LFA-1 is a binding domain for JAM-A. It was 
therefore hypothesized that recombinant I domain alone is sufficient for binding to JAM-A. 
LFA-1 on resting cells does not bind spontaneously to its ligands, but needs to assume an 
open high-affinity conformation as a result of stimulation. In order to study interactions with I 
domain alone, I domain locked in the open high-affinity conformation by the introduction of a 
disulfide bond was used. In adhesion assays on immobilized locked-open LFA-1 I domain, 
CHO transfectants expressing JAM-A but not vector controls showed binding to locked-open 
I domain. These data have shown that the isolated locked-open LFA-1 I domain is sufficient 
to support binding to the ligand JAM-A. The isolated locked-open LFA-1 I domain is also 
sufficient for binding to the ligands ICAM-1 and -3 (Lu et al., 2001; Shimaoka et al., 2001).  
 
JAM-A binding to locked-open I domain was specifically mediated by the open 
conformation, since reduction of the disulfide bond with DTT abolished adhesion. 
Conformational change in the I domain of LFA-1 is therefore of importance not only for the 
interaction with ICAM-1, but also for the interaction with JAM-A. In the interaction with 
ICAM-1, a change in the conformation of the LFA-1 I domain has been shown to control the 
transition from rolling adhesion to firm adhesion, since only the low-affinity closed 
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conformation mediates rolling, whereas the high-affinity open conformation supports firm 
arrest (Salas et al., 2002).  
 
The locked-open I domain was resistant to inhibition by the small molecule antagonist 
BIRT377 (Fig. III-13). Structural studies show that BIRT377 binds to the LFA-1 I domain at 
a site distal to the MIDAS and does not antagonize in a direct competitive mode but rather in 
an indirect mechanism. It has been hypothesized that binding of BIRT377 stabilizes the low-
affinity closed conformation by blocking the downward shift of the C-terminal α-helix that 
occurs in the transition from the closed to the open conformation and thereby inhibiting ligand 
binding (Last-Barney et al., 2001; Woska et al., 2001). The data in this study confirmed that 
BIRT377 does not bind to locked-open LFA-1 I domain, since binding of CHO transfectants 
expressing JAM-A to immobilized locked-open I domain was not inhibited by BIRT377. 
Other small molecule antagonist have been described to antagonize the function of LFA-1 in a 
similar mode of inhibition. Statins, which are a drug class that inhibits the HMG-CoA (3-
hydroxy-3-methylglutaryl coenzyme A) reductase, are commonly prescribed to reduce plasma 
cholesterol levels and consequently the risk of cardiovascular disease. In addition, some 
statins have been found to inhibit the interactions between LFA-1 and ICAM-1. The statin 
lovastatin inhibits binding of LFA-1 to ICAM-1 by binding to the LFA-1 I domain (Kallen et 
al., 1999). Like BIRT377, lovastatin binds the closed but not the open conformation of the 
LFA-1 I domain (Lu et al., 2001). The statins simvastatin and mevastatin inhibit LFA-1 
interactions with ICAM-1 by binding at the same site in the LFA-1 I domain as lovastatin 
(Weitz-Schmidt et al., 2001).   
 
Further evidence for a direct interaction between the locked open LFA-1 I domain and 
JAM-A was provided by a solid-phase binding experiment (Fig. III-14B). The experiment 
showed a dose-dependent binding of soluble JAM-A.Fc to immobilized locked-open LFA-1 I 
domain with an equilibrium dissociation binding constant of ∼0.5 µM. This binding constant 
is within the range of dissociation constants (0.13-0.55 µM) published for the LFA-1/ICAM-1 
interaction (Lupher et al., 2001; Shimaoka et al., 2001; Tominaga et al., 1998). The 
interaction of LFA-1 with JAM-A was Mg2+ ion dependent, since binding could be almost 
completely inhibited by addition of EDTA. The finding that the interaction between 
JAM-A.Fc and locked-open I domain is dependent on divalent cation demonstrate 
considerable similarity in the interactions of LFA-1 with JAM-A and ICAM-1, -2, and -3. 
Thus, a coordination of binding involving divalent metal ions appears to be the principal 
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mechanism mediating the interaction between LFA-1 and its ligands. The cation is 
coordinated in the metal ion-dependent adhesion site (MIDAS) in the I domain.  
 
The binding between LFA-1 and ICAM-1 requires the acidic amino acid residue E34 in 
ICAM-1 (Stanley and Hogg, 1998; Staunton et al., 1990). Crystal structures of the locked-
open LFA-1 I domain and its complex with ICAM-1, have shown that a Mg2+ ion coordinated 
in the MIDAS in the I domain directly coordinates E34 of ICAM-1. Conformational changes 
in the I domain upon conversion from the closed to the open conformation leads to a dramatic 
reorientation of the E241 side chain which enables a salt bridge between E241 in the I domain 
and K39 in ICAM-1 (Shimaoka et al., 2003). By analogy to the interaction between LFA-1 
and ICAM-1, a yet to be identified acidic amino acid residue in JAM-A may be involved in 
the interaction with LFA-1. Possible candidates could be residue E163 or D169 in the domain 
D2 of human JAM-A, and are subject to further investigation. The binding kinetics for these 
mutants could then be analysed using surface plasmon resonance (SPR) based technology.  
 
 
IV.2 Involvement of JAM-A in LFA-1 mediated steps of mononuclear 
cell recruitment  
Junctional adhesion molecule-A (JAM-A) is a member of the immunoglobulin superfamily 
(IgSF) and is composed of two Ig-like loops in the extracellular domain, a single-pass 
transmembrane region, and a short cytoplasmic tail with a PDZ binding domain. JAM-A is 
expressed in leukocytes, platelets, endothelial, and epithelial cells. In endothelial and 
epithelial cells, JAM-A localizes at tight junctions and participates in the contact between 
neighboring cells via homophilic interactions. Upon inflammatory stimulation with cytokines, 
JAM-A is redistributed from the junctions to the cell surface. Several reports have suggested a 
role of JAM-A in leukocyte adhesion and diapedesis (see I.4.6). Endothelial JAM-A and 
leukocyte JAM-A may contribute through homophilic interactions in cis and in trans. In 
addition, this may involve heterophilic interactions of endothelial JAM-A with its integrin 
receptor LFA-1. Furthermore, leukocyte JAM-A may trigger intracellular signaling events, 
for example by interactions with PDZ domain containing proteins or through a cis interaction 
of the JAM-A cytoplasmic part with the cytoplasmic part of LFA-1 as suggested from yeast 
two-hybrid system data (Ostermann et al., 2002). In this study, the involvement of JAM-A in 
LFA-1 mediated steps of mononuclear cell recruitment was further analyzed.  
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The involvement of JAM-A in distinct steps of mononuclear cell recruitment was analyzed 
using soluble JAM-A.Fc protein as a competitive inhibitor. Soluble JAM-A.Fc protein was 
expressed as a chimeric protein containing the extracellular part of human JAM-A fused to 
the Fc part of human IgG1. To exclude inhibitory effects as a result of the Fc part of 
JAM-A.Fc, several controls were performed. Human IgG and the chimeric protein CD30.Fc, 
which binds to the membrane protein CD30R on mononuclear cells, were used as control 
proteins. The adhesion of Jurkat T cells to immobilized ICAM-1 was dose-dependently 
inhibited by incubation with sJAM-A.Fc protein. With ICAM-1 as an exclusive substrate for 
T cell adhesion, an interference of homophilic JAM-A interactions by JAM-A.Fc could be 
excluded in this assay. This indicates that sJAM-A.Fc exerts its inhibitory function by 
antagonizing the LFA-1 interactions with ICAM-1 via binding to LFA-1. The binding of 
sJAM-A.Fc to LFA-1 involve the I domain of LFA-1 as shown in this study. However, it can 
not be excluded that sJAM-A.Fc interacts with JAM-A on the surface of leukocytes, thereby 
triggering JAM-A-mediated signaling events. The cytoplasmic domain of JAM-A contains a 
PDZ binding domain with many identified interacting partners (I.4.5). An intracellular 
signaling pathway could involve Rap1. The small GTPase Rap1 is an activator of β1 integrins. 
A region in the cytoplasmic domain of the αL subunit of LFA-1 has been identified as critical 
for Rap1-dependent adhesion and transmigration (Tohyama et al., 2003). A recent report 
showed a colocalization of Rap1 and JAM-A, and that knockdown of JAM-A expression 
using a siRNA based approach resulted in decreased Rap1 activity (Mandell et al., 2005). It 
was suggested that JAM-A is connected to the Rap1 pathway through a PDZ domain 
containing protein. A candidate could be AF-6, which has been reported to interact with both 
Rap1 (Boettner et al., 2000) and JAM-A (Ebnet et al., 2000). In another report, data from a 
yeast two-hybrid system has suggested a direct cis interaction between the JAM-A 
cytoplasmic part and the cytoplasmic part of LFA-1 (Ostermann et al., 2002). Such an 
interaction may directly regulate LFA-1 activity or be involved in intracellular signaling 
pathways affecting LFA-1 affinity for ICAM-1. A similar cytoplasmic cis interaction has 
been described for the cell adhesion molecule PECAM-1 (CD31) and its interaction with the 
integrin αVβ3 (Wong et al., 2000). Several controls demonstrated that the effects observed 
with sJAM-A.Fc was not due to the interaction of the Fc portion of the chimeric protein with 
leukocyte Fc receptors. A human IgG control and a chimeric protein containing CD30 fused 
to the Fc part of human IgG1, had no significant effects under the same assay conditions.  
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Furthermore, the adhesion of monocytic MM6 cells to proinflammatory stimulated HUVEC 
monolayers was analyzed. In order to redistribute JAM-A to the apical surface of endothelial 
cells, endothelial monolayers were costimulated with the proinflammatory cytokines TNF-α 
and IFN-γ, which also have been shown to upregulate the expression of VCAM-1 on 
endothelial cells (Carlos et al., 1990; De Caterina et al., 2001; Osborn et al., 1989). Treatment 
of monocytes with sJAM-A.Fc alone had no effect, but after blocking of VLA-4 interactions 
with VCAM-1 expressed on inflamed endothelium, treatment with sJAM-A.Fc reduced 
monocyte adhesion. Thus, the VLA-4-independent adhesion of monocytic MM6 cells on 
HUVEC monolayers was decreased by treatment with soluble JAM-A.Fc.  
 
Flow chamber experiments with T cells arrest on inflamed endothelium confirmed the 
inhibitory effect of sJAM-A.Fc on leukocyte recruitment under more physiological 
conditions. In order to analyze LFA-1-mediated arrest only, T cells were treated with a 
blocking mAb specific for VLA-4 to exclude interactions with VCAM-1 expressed on 
inflamed endothelium. Arrest was triggered by immobilization of the chemokine SDF-1α on 
endothelium, which trigger arrest by interactions with the chemokine receptor CXCR4 
expressed on T cells (Campbell et al., 1998). After blocking of VLA-4, the arrest of memory 
T cell  was mediated by LFA-1, as seen using a blocking mAb specific for LFA-1, which 
reduced arrest to background levels without immobilized SDF-1α. Memory T cell arrest on 
inflamed endothelium in flow was inhibited in a dose-dependent manner by sJAM-A.Fc 
treatment of T cells. The inhibition after treatment with sJAM-A.Fc was higher than with a 
blocking Ab specific for JAM-A. The high degree of inhibition achieved by sJAM-A.Fc is 
likely because of the fact that shielding LFA-1 by sJAM-A.Fc, as seen in static adhesion 
assays on ICAM-1, may impair engagement of LFA-1 not only with JAM-A but also with 
ICAM-1 or ICAM-2 expressed on inflamed endothelium and contributing to efficient arrest.  
 
Transmigration assays was used to study the effect of sJAM-A.Fc on memory T cell 
migration across HUVEC monolayers in response to SDF-1α. Using a blocking mAb specific 
for LFA-1, a major role of LFA-1 in transendothelial migration was shown. This is in 
accordance with previously reports showing a major role of LFA-1 in transendothelial 
migration of mononuclear cells (Kavanaugh et al., 1991; Meerschaert and Furie, 1995; Roth 
et al., 1995; Weber et al., 1997a). Treatment of T cells with sJAM-A.Fc reduced 
transendothelial migration. Again, the effect of sJAM-A.Fc was larger that the effect of a 
blocking Ab specific for JAM-A, probably due to shielding of LFA-1 by binding of sJAM-
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A.Fc to the LFA-1 I domain as seen in adhesion and flow assays. Several controls 
demonstrated that the effects observed with sJAM-A.Fc was not due to the Fc part of the 
chimeric protein. A human IgG control and a CD30.Fc chimeric protein had no significant 
effects under the same assay conditions.  
 
Although homophilic JAM-A interactions may also contribute in leukocyte transmigration, 
these results suggest a major role of interactions between LFA-1 and its ligands in T cell 
migration. Several reports have shown a role of JAM-A in leukocyte diapedesis. Using the 
blocking mAb BV11 specific for JAM-A, migration of monocytes (Martin-Padura et al., 
1998) and neutrophils (Del Maschio et al., 1999) is reduced.  
 
These data provide the first evidence that soluble JAM-A.Fc can inhibit distinct steps of 
LFA-1-mediated mononuclear cell recruitment on inflamed endothelium. Other investigators 
have also used chimeras of adhesion molecules fused with the Fc domain of human IgG1 to 
study adhesive interactions in inflammation. A PECAM-1.Fc chimeric protein inhibits 
emigration of monocytes and neutrophils into the inflamed peritoneal cavity in vivo in a 
mouse model (Liao et al., 1997). Furthermore, a CD36.Fc chimera inhibits oxidized low-
density lipoprotein (oxLDL) induced monocyte adhesion to ICAM-1 (Stewart and Nagarajan, 
2006).  
 
IV.3 Upregulation of JAM-A expression on early atherosclerotic 
endothelium  
JAM-A is expressed in leukocytes and platelets, and in endothelial and epithelial cells, where 
JAM-A localizes to tight junctions. JAM-A has a broad expression pattern and has been 
detected in endothelial and epithelial cells in tissue that include liver, kidney, pancreas, heart, 
brain, lymph nodes, intestine, lung, and placenta (I.4.1). Since mononuclear cell recruitment 
is important not only in inflammatory recruitment, but also in the development and 
progression of atherosclerosis (I.5), the expression of JAM-A on atherosclerotic endothelium 
was analyzed in this study.  
 
Apolipoprotein E (apoE) is involved in cholesterol transport and knockdown of this gene is 
associated with elevated levels of plasma cholesterol. ApoE-deficient (apoE-/-) mice fed a 
high fat Western-type diet develop marked hypercholesterolemia (Zhang et al., 1992). At the 
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age of 10 weeks, apoE-deficient mice have developed atherosclerotic lesions in the aorta, and 
the coronary and pulmonary arteries (Plump et al., 1992). In this study, JAM-A expression on 
endothelium in carotid arteries of wild-type mice was compared with expression in carotid 
arteries of apoE-/- mice fed a Western diet for 6 weeks. At this timepoint, the endothelium 
develop early stages of atherosclerosis, but without manifest lesions. Using double 
immunofluorescence staining for JAM-A and the endothelial cell marker PECAM-1 (CD31), 
JAM-A expression in endothelial cells was analyzed. Compared to wild-type endothelium, an 
upregulation of JAM-A was found on atherosclerotic endothelium of arteries from apoE-/- 
mice. This up-regulation of JAM-A expression was confirmed by real-time RT-PCR analysis, 
which showed a 2.6-fold increase of JAM-A mRNA transcripts in atherosclerotic arteries of 
apoE-/- mice compared with arteries of wild-type mice. These results show, that under 
hyperlipidemia, JAM-A expression is upregulated, which might influence the development of 
atherosclerosis. In a previously report, a similar hypercholesterol-associated upregulation of 
the cell adhesion molecule VCAM-1 was found (Nakashima et al., 1998). In contrast, 
ICAM-1 expression is not upregulated as a response to hyperlipidemia but upregulated at 
lesion-prone sites (Nakashima et al., 1998), which could be related to local changes in blood 
flow, since ICAM-1 expression can be induced by shear stress (Nagel et al., 1994). A role of 
JAM-A at later stages of atherosclerosis and for plaque rupture was suggested by 
(Papaspyridonos et al., 2006), who found a 2.2-fold upregulation of JAM-A expression in 
unstable areas versus stable areas of human atherosclerotic plaque obtained from the same 
patient.  
 
IV.4 Atherogenic recruitment of mononuclear cells  
Since JAM-A was found to be upregulated on atherosclerotic endothelium, the involvement 
of JAM-A in atherogenic recruitment of mononuclear cells was investigated. In ex vivo 
perfusion assay, the VLA-1-independent accumulation of monocytes and T cells to carotid 
arteries of apoE-/- mice was inhibited by sJAM-A.Fc (Fig. III-22 and Fig. III-23). The VLA-4-
dependent accumulation was not inhibited by sJAM-A.Fc, in accordance with a previous 
study showing a prominent function of VLA-4/VCAM-1 interactions in arrest of mononuclear 
cells on early atherosclerotic endothelium (Ramos et al., 1999). The combinatory effect of a 
blocking mAb specific for VLA-4 and a blocking mAb specific for LFA-1 on monocyte and 
T cell adhesion, showed that sJAM-A.Fc may exert its function by blocking LFA-1 
interactions with ligands expressed on atherosclerotic endothelium, e.g. ICAM-1 and JAM-A.  
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IV.5 Role of endothelial JAM-A  
Human JAM-A is expressed in both leukocytes and endothelial cell, and engaged in both 
homophilic interactions (in cis and in trans) and heterophilic interactions with its integrin 
receptor LFA-1. To address the role of endothelial JAM-A more directly, aortic endothelial 
cells from JAM-A-deficient mice was isolated and cultured. Endothelial monolayers were 
costimulated with TNF-α and IFN-γ. Compared with JAM-A+/+ endothelial cells, JAM-A-/- 
endothelial cells supported less monocyte adhesion (Fig. III-26). In addition, monocyte 
transmigration was substantially reduced. These data substantiate a role of endothelial JAM-A 
in inflammatory recruitment of mononuclear cells and in atherogenic recruitment after 
JAM-A upregulation on atherosclerotic endothelium.  
 
These data have shown that endothelial JAM-A serves as an endothelial receptor for 
monocyte transmigration. Other identified endothelial receptors for leukocyte transmigration 
are PECAM-1 (Muller et al., 1993) and CD99 (Schenkel et al., 2002). Both proteins are 
expressed at endothelial junctions and engage in homophilic interactions with protein 
expressed on the surface of leukocytes. Such homophilic interactions could be important in 
directing the passage of leukocytes through junctions. In addition, JAM-A may be involved in 
integrin-mediated active guiding of leukocytes through junctions by interactions with LFA-1.  
 
Organization and composition of endothelial junctions varies along the vascular tree. Some 
reports suggest that endothelial JAM-A is not important in leukocyte adhesion and migration 
in all tissues. Endothelial JAM-A expressed in the liver has been found to important in 
neutrophil transmigration (Khandoga et al., 2005). In contrast, neutrophil migration is 
independent on JAM-A expression on endothelial cells isolated from lung (Corada et al., 
2005). Since different types of vessels have different structures and molecular compositions, 
it is possible that junctional molecules could act in parallel or compensate for each other. For 
example, other members of the JAM family may substitute for JAM-A in some tissues as for 
example the lung, where JAM-B and JAM-C were both detected in endothelial cells (Corada 
et al., 2005).  
 
IV.6 Perspectives 
JAM-A expressed on endothelial cells may exert its function through interactions with both 
leukocytic JAM-A and LFA-1. In addition, JAM-A-mediated intracellular signaling pathways 
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in both leukocytes and endothelial cells may play a role in leukocyte adhesion and 
transmigration. An important aspect not investigated in this study is the functional role of 
JAM-A-mediated intracellular signaling pathways. The cytoplasmic domain of JAM-A 
contains the consensus motif for several types of kinases including protein kinase C (PKC). In 
platelets, JAM-A is phosphorylated by PKC upon activation (Ozaki et al., 2000). Whether 
such intracellular signal pathways are also important in leukocytes remains to be clarified. 
The cytoplasmic domain of leukocytic JAM-A has been found to interact in cis with the 
cytoplasmic domain of LFA-1 (Ostermann et al., 2002). The functional role of this interaction 
and whether this interaction directly regulate LFA-1 affinity or avidity remains to be clarified.  
 
Transendothelial migration of leukocytes requires a temporary opening of the adhesive 
complex of tight junctions. JAM-A homodimers interact via the membrane-distal domain D1 
in trans with JAM-A homodimers from an neighboring cell. Since LFA-1 interacts with the 
membrane-proximal domain D2 of JAM-A, leukocytic LFA-1 may serve to intercept JAM-A 
homophilic interactions at junctions during leukocyte transmigration. It can be speculated that 
after binding of LFA-1 to D2 of JAM-A, endothelial JAM-A dimers are captured by JAM-A 
dimers on leukocytes, leading to a temporary opening of the tight junction. Thus being 
strategically located at tight junctions, JAM-A might function as a molecular zipper for 
leukocyte transmigration via a complex interplay of its heterophilic and homophilic 
interaction in cis and in trans. The exact interplay of these interactions and a possible role of 
an interaction in cis between the cytoplasmic domains of JAM-A and LFA-1 should be 
addressed in future studies. For these studies, the surface plasmon resonance based 
technology would be very useful for kinetic measurements of these interactions.  
 
The data in this study provide the first evidence that the I domain of LFA-1 contains a 
functional binding domain for JAM-A, and that the I domain of LFA-1 is sufficient and 
required for functional interaction of LFA-1 with JAM-A. Inhibitors specifically interfering 
with the interactions between LFA-1 and JAM-A may provide sufficient selectivity to block 
inflammatory recruitment of mononuclear cells without unwanted and deleterious side effects. 
The identification of the LFA-1 I domain as the binding domain for JAM-A, and the finding 
that the functional interaction with JAM-A is mediated by the open conformation of the I 
domain, may give rise to a novel target site for the development of anti-inflammatory 
therapies. Together with an upregulation of JAM-A on atherosclerotic endothelium and a 
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functional contribution of JAM-A to atherogenesis, these findings may also have implications 
for the prevention of cardiovascular disease.  
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V.1  Summary 
Junctional adhesion molecule-A (JAM-A) is a ligand of the integrin lymphocyte function-
associated antigen-1 (LFA-1). In this study the JAM-A binding domain in LFA-1 was 
identified and the involvement of JAM-A in inflammatory recruitment of mononuclear cells 
was analyzed. Furthermore, a functional contribution of JAM-A to atherogenesis was 
investigated.  
 
By deletion of the I domain in the αL subunit of LFA-1 and expression of this αL mutant in 
αL-deficient Jurkat J-β2.7 T cells, it was here demonstrated that the I domain of LFA-1 is 
crucial for adhesion to immobilized JAM-A. This was substantiated by blocking the 
stimulated adhesion of T cells or monocytes to JAM-A using the I domain-directed mAb 
TS1/22 or the small molecule antagonist BIRT377, which stabilizes the low-affinity 
conformation of the I domain. The immobilized LFA-1 I domain locked in the open high-
affinity conformation was sufficient to support adhesion of transfected Chinese hamster ovary 
cells expressing human JAM-A. A solid-phase binding assay confirmed a direct interaction of 
recombinant JAM-A with immobilized LFA-1 I domain locked in the open high-affinity 
conformation. These data demonstrated that the I domain of LFA-1 is sufficient and required 
for the functional interactions of LFA-1 with JAM-A.  
 
Using soluble JAM-A.Fc chimeric protein as a competitive inhibitor, the involvement of 
JAM-A in distinct steps of mononuclear cells recruitment was analyzed. Adhesion assays 
revealed that LFA-1-mediated binding of T cells or monocytes to immobilized ICAM-1 or 
cytokine-costimulated endothelium was inhibited in a dose-dependently fashion by soluble 
JAM-A.Fc. Similarly, soluble JAM-A.Fc reduced the LFA-1-mediated SDF-1α-triggered 
arrest under flow conditions and transendothelial chemotaxis of T cells. These data have 
shown that soluble JAM-A can be effectively applied to inhibit distinct steps of inflammatory 
recruitment of mononuclear cells.  
 
Immunofluorescence and real-time RT-PCR analysis showed an upregulation of JAM-A 
expression on early atherosclerotic endothelium of carotid arteries from apolipoprotein E-
deficient (apoE-/-) mice fed a high fat Western-type diet. In ex vivo perfusion assays, soluble 
JAM-A.Fc inhibited the VLA-4-independent accumulation of mononuclear cells on 
atherosclerotic endothelium. Together with the upregulation of JAM-A on atherosclerotic 
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endothelium, this suggests a functional contribution of JAM-A to atherogenesis. The role of 
endothelial JAM-A in atherogenic recruitment was further substantiated by an attenuation of 
monocyte arrest and transmigration on activated JAM-A-/-apoE-/- versus JAM-A+/+apoE-/- 
mouse aortal endothelial cells in vitro. The findings from this work may be helpful in 
designing new strategies for the development of anti-inflammatory therapies.  
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V.2  Zusammenfassung 
Junctional adhesion molecule-A (JAM-A) ist ein Ligand für das Integrin Lymphocyte 
function-associated antigen-1 (LFA-1). In dieser Arbeit wurde die JAM-A Bindungsdomäne 
des LFA-1 identifiziert und die Beteiligung von JAM-A an der inflammatorischen 
Rekrutierung von mononuklären Zellen analysiert. Außerdem wurde eine Beteiligung von 
JAM-A in der Atherogenese untersucht.  
 
Durch Deletion der I Domäne in der αL Kette  von LFA-1 und Expression dieses αL Mutanten 
in αL-defizienten Jurkat J-β2.7 T-Zellen wurde gezeigt, dass die LFA-1 I Domäne für die 
Adhäsion an immobilisiertem JAM-A notwendig ist. Dies wurde durch Blockierung der 
stimulierten Adhäsion von T-Zellen oder Monozyten an JAM-A bestätigt. Die Blockierung 
wurde mit dem gegen die I Domäne gerichteten mAb TS1/22 oder dem kleinen molekularen 
Antagonisten BIRT377, der die Konformation der I Domäne mit niedriger Affinität 
stabilisiert, erreicht. Die immobilisierte LFA-1 I Domäne, geschlossen in der offenen 
Konformation mit hoher Affinität, war ausreichend, um die Adhäsion von JAM-A 
exprimierenden Chinese Hamster Ovary Zell-Transfektanten zu unterstützen. Ein solid-phase 
Bindungs-Assay bestätigte eine direkte Interaktion zwischen den rekombinanten JAM-A und 
der immobilisierten LFA-1 I Domäne geschlossen in der offenen Konformation mit hohe 
Affinität. Diese Daten zeigten, dass die LFA-1 I Domäne ausreichend und notwendig für 
funktionelle Interaktionen des LFA-1 Integrin mit JAM-A ist.  
 
Durch Verwendung von JAM-A.Fc Chimären Proteinen als kompetitive Inhibitoren wurde 
die Beteiligung von JAM-A an verschiedenen Schritten der Rekrutierung mononuklärer 
Zellen untersucht. In Adhäsions-Assays wurde gezeigt, dass die LFA-1 vermittelte Bindung 
von T-Zellen und Monozyten an immobilisiertem ICAM-1 oder ko-stimuliertem Endothel 
dosisabhängig von löslichem JAM-A.Fc inhibiert wurde. Ebenso wurde der LFA-1 
vermittelte und SDF-1α induzierte Arrest unter Flussbedingungen und die transendotheliale 
Chemotaxis von T-Zellen durch lösliches JAM-A.Fc reduziert. Diese Daten haben gezeigt, 
dass lösliches JAM-A.Fc verschiedene Schritte der inflammatorischen Rekrutierung 
mononuklärer Zellen inhibieren kann.  
 
Immunfluoreszenz und real-time RT-PCR Analysen zeigten eine Hochregulation der JAM-A 
Expression auf frühatherosklerotischem Endothel von Carotiden Apolipoprotein E-defizienter 
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(apoE-/-) Mäuse, die mit einer fettreichen Western-Typ Diät ernährt wurden. In ex vivo 
Perfusions-Assays inhibierte lösliches JAM-A.Fc die VLA-4-unabhängige Akkumulation von 
mononuklären Zellen auf atherosklerotischem Endothel. Zusammen mit der Hochregulation 
von JAM-A im atherosklerotischem Endothel deutet dies auf eine funktionelle Beteiligung 
von JAM-A in der Atherogenese hin. Die Rolle von endothelialem JAM-A in der 
atherogenischen Rekrutierung wurde durch einen reduzierten Monozytenarrest und eine 
verminderte Transmigration auf aktivierten JAM-A-/-apoE-/- im vergleich zu JAM-A+/+apoE-/- 
murinen Endothelzellen in vitro bestätigt. Die Ergebnisse dieser Arbeit könnten zu einem 
neuen Ansatz für die Entwicklung von anti-inflammatorischen Therapien führen. 
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